Activation	O
domain	O
requirements	O
for	O
disruption	O
of	O
Epstein-Barr	O
virus	O
latency	O
by	O
ZEBRA	B-protein
.	O

Latent	O
infection	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
can	O
be	O
disrupted	O
by	O
expression	O
of	O
the	O
EBV	B-protein
ZEBRA	I-protein
protein	I-protein
.	O

ZEBRA	B-protein
,	O
a	O
transcriptional	O
activator	O
,	O
initiates	O
the	O
EBV	O
lytic	O
cascade	O
by	O
activating	O
viral	O
gene	O
expression	O
.	O

ZEBRA	B-protein
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O

The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O

ZEBRA	B-protein
activation	O
can	O
be	O
replaced	O
by	O
a	O
heterologous	B-protein
acidic	I-protein
,	I-protein
proline-rich	I-protein
,	I-protein
or	I-protein
glutamine-rich	I-protein
activation	I-protein
domain	I-protein
.	O

ZEBRA	B-protein
activation	O
domain	O
swap	O
constructs	O
retain	O
ZEBRA	B-protein
's	O
native	O
abilities	O
to	O
activate	O
specific	O
EBV	B-DNA
promoters	I-DNA
,	O
to	O
disrupt	O
EBV	O
latency	O
,	O
and	O
to	O
stimulate	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

Additional	O
work	O
,	O
employing	O
sequential	O
and	O
internal	O
deletions	O
of	O
ZEBRA	B-protein
's	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
,	O
indicates	O
that	O
its	O
separate	O
activities	O
are	O
not	O
attributable	O
to	O
specific	O
subdomains	B-protein
but	O
are	O
spread	O
throughout	O
its	O
N	B-protein
terminus	I-protein
and	O
therefore	O
can	O
not	O
be	O
inactivated	O
by	O
deleting	O
localized	O
regions	O
.	O

JOURNAL	NULL
OF	NULL
VirRoLOGY	NULL
,	NULL
Sept.	NULL
1997	NULL
,	NULL
p.	NULL
6547-6554	NULL
0022-538X	NULL
,	NULL
/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Activation	NULL
Domain	NULL
Requirements	NULL
for	NULL
Disruption	NULL
of	NULL
Epstein-Barr	NULL
Virus	NULL
Latency	NULL
by	NULL
ZEBRA	NULL
SRDJAN	NULL
ASKOVIC	NULL
anp	NULL
RAY	NULL
BAUMANN®*	NULL
Department	NULL
of	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Mississippi	NULL
Medical	NULL
Center	NULL
,	NULL
Jackson	NULL
,	NULL
Mississippi	NULL
39216	NULL
Received	NULL
4	NULL
April	NULL
1997/Accepted	NULL
28	NULL
May	NULL
1997	NULL
Latent	NULL
infection	NULL
of	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
can	NULL
be	NULL
disrupted	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
EBV	NULL
ZEBRA	NULL
protein	NULL
.	NULL

ZEBRA	NULL
,	NULL
a	NULL
transcriptional	NULL
activator	NULL
,	NULL
initiates	NULL
the	NULL
EBV	NULL
lytic	NULL
cascade	NULL
by	NULL
activating	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

ZEBRA	NULL
is	NULL
also	NULL
indispensable	NULL
for	NULL
viral	NULL
replication	NULL
and	NULL
binds	NULL
directly	NULL
to	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
.	NULL

The	NULL
studies	NULL
described	NULL
herein	NULL
demonstrate	NULL
that	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
ZEBRA	NULL
is	NULL
not	NULL
unique	NULL
and	NULL
can	NULL
be	NULL
replaced	NULL
by	NULL
a	NULL
heterologous	NULL
acidic	NULL
,	NULL
proline-rich	NULL
,	NULL
or	NULL
glutamine-rich	NULL
activation	NULL
domain	NULL
.	NULL

ZEBRA	NULL
activation	NULL
domain	NULL
swap	NULL
constructs	NULL
retain	NULL
ZEBRA	NULL
's	NULL
native	NULL
abilities	NULL
to	NULL
activate	NULL
specific	NULL
EBV	NULL
promoters	NULL
,	NULL
to	NULL
disrupt	NULL
EBV	NULL
latency	NULL
,	NULL
and	NULL
to	NULL
stimulate	NULL
replication	NULL
at	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
.	NULL

Additional	NULL
work	NULL
,	NULL
employing	NULL
sequential	NULL
and	NULL
internal	NULL
deletions	NULL
of	NULL
ZEBRA	NULL
's	NULL
N-terminal	NULL
activation	NULL
domain	NULL
,	NULL
indicates	NULL
that	NULL
its	NULL
separate	NULL
activities	NULL
are	NULL
not	NULL
attributable	NULL
to	NULL
specific	NULL
subdomains	NULL
but	NULL
are	NULL
spread	NULL
throughout	NULL
its	NULL
N	NULL
terminus	NULL
and	NULL
therefore	NULL
can	NULL
not	NULL
be	NULL
inactivated	NULL
by	NULL
deleting	NULL
localized	NULL
regions	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
,	NULL
a	NULL
ubiquitous	NULL
human	NULL
herpesvirus	NULL
,	NULL
is	NULL
the	NULL
causative	NULL
agent	NULL
of	NULL
infectious	NULL
mononucleosis	NULL
.	NULL

It	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
a	NULL
cofactor	NULL
in	NULL
the	NULL
genesis	NULL
of	NULL
several	NULL
neoplasms	NULL
and	NULL
is	NULL
strongly	NULL
associated	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
in	NULL
immunocompromised	NULL
individuals	NULL
(	NULL
33	NULL
)	NULL
.	NULL

EBV	NULL
infects	NULL
and	NULL
establishes	NULL
lifelong	NULL
latency	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

During	NULL
latency	NULL
the	NULL
viral	NULL
genome	NULL
is	NULL
maintained	NULL
as	NULL
a	NULL
multiple-copy	NULL
episome	NULL
,	NULL
and	NULL
only	NULL
a	NULL
small	NULL
fraction	NULL
of	NULL
EBV	NULL
's	NULL
genes	NULL
are	NULL
expressed	NULL
.	NULL

Replication	NULL
of	NULL
latent	NULL
viral	NULL
DNA	NULL
occurs	NULL
at	NULL
a	NULL
low	NULL
level	NULL
and	NULL
is	NULL
initiated	NULL
at	NULL
the	NULL
origin	NULL
of	NULL
plasmid	NULL
maintenance	NULL
(	NULL
oriP	NULL
)	NULL
(	NULL
44	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
EBV	NULL
enters	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
most	NULL
EBV	NULL
genes	NULL
are	NULL
ex-pressed	NULL
;	NULL
DNA	NULL
replication	NULL
occurs	NULL
at	NULL
a	NULL
much	NULL
higher	NULL
level	NULL
and	NULL
is	NULL
initiated	NULL
at	NULL
a	NULL
unique	NULL
origin	NULL
of	NULL
replication	NULL
designated	NULL
oriLyt	NULL
(	NULL
9-11	NULL
,	NULL
14	NULL
,	NULL
20	NULL
,	NULL
22	NULL
,	NULL
23	NULL
,	NULL
29	NULL
,	NULL
30	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Initiation	NULL
of	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
in	NULL
latently	NULL
infected	NULL
B	NULL
lymphocytes	NULL
is	NULL
a	NULL
rare	NULL
event	NULL
.	NULL

However	NULL
,	NULL
diverse	NULL
agents	NULL
can	NULL
activate	NULL
latent	NULL
EBV	NULL
,	NULL
including	NULL
phorbol	NULL
esters	NULL
,	NULL
»	NULL
-butyrate	NULL
,	NULL
anti-immu-noglobulin	NULL
,	NULL
superinfection	NULL
with	NULL
another	NULL
virus	NULL
,	NULL
or	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
EBV	NULL
ZEBRA	NULL
protein	NULL
(	NULL
BamHI	NULL
Z	NULL
Epstein-Barr	NULL
replication	NULL
activator	NULL
;	NULL
also	NULL
known	NULL
as	NULL
EB1	NULL
and	NULL
Zta	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

ZEBRA	NULL
is	NULL
unique	NULL
among	NULL
herpesvirus	NULL
activators	NULL
in	NULL
its	NULL
capacity	NULL
to	NULL
disrupt	NULL
viral	NULL
latency	NULL
.	NULL

ZEBRA	NULL
,	NULL
a	NULL
bZIP	NULL
-like	NULL
transcriptional	NULL
activator	NULL
,	NULL
binds	NULL
as	NULL
a	NULL
homodimer	NULL
to	NULL
ZEBRA-responsive	NULL
elements	NULL
(	NULL
ZREs	NULL
)	NULL
which	NULL
are	NULL
located	NULL
upstream	NULL
of	NULL
specific	NULL
EBV	NULL
genes	NULL
and	NULL
also	NULL
within	NULL
the	NULL
oriLyt	NULL
region	NULL
(	NULL
30	NULL
)	NULL
.	NULL

ZEBRA	NULL
performs	NULL
a	NULL
dual	NULL
role	NULL
in	NULL
the	NULL
EBV	NULL
life	NULL
cycle	NULL
,	NULL
functioning	NULL
both	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
and	NULL
as	NULL
an	NULL
origin	NULL
binding	NULL
protein	NULL
essential	NULL
for	NULL
EBV	NULL
DNA	NULL
replication	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
ZEBRA	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
proteins	NULL
,	NULL
including	NULL
TATA-binding	NULL
protein	NULL
(	NULL
TBP	NULL
)	NULL
,	NULL
TFIIA	NULL
,	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
NF-kB/p65	NULL
,	NULL
and	NULL
p53	NULL
(	NULL
21	NULL
,	NULL
31	NULL
,	NULL
42	NULL
,	NULL
47	NULL
)	NULL
.	NULL

ZEBRA	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
alter	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
gene	NULL
expression	NULL
and	NULL
to	NULL
arrest	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
epithelial	NULL
cells	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

The	NULL
ZEBRA	NULL
protein	NULL
consists	NULL
of	NULL
three	NULL
exons	NULL
which	NULL
roughly	NULL
correspond	NULL
to	NULL
its	NULL
three	NULL
functional	NULL
domains	NULL
.	NULL

The	NULL
DNA	NULL
recognition	NULL
and	NULL
dimerization	NULL
domains	NULL
are	NULL
located	NULL
in	NULL
exons	NULL
2	NULL
and	NULL
3	NULL
,	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
601	NULL
)	NULL
984-1713	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
601	NULL
)	NULL
984-1708	NULL
.	NULL

E-mail	NULL
:	NULL
yar	NULL
@	NULL
fiona.umsmed.edu	NULL
.	NULL

6547	NULL
respectively	NULL
,	NULL
while	NULL
exon	NULL
1	NULL
contains	NULL
the	NULL
activation	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Deletion	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
activation	NULL
domain	NULL
is	NULL
encompassed	NULL
within	NULL
amino	NULL
acids	NULL
25	NULL
to	NULL
152	NULL
(	NULL
18	NULL
)	NULL
,	NULL
with	NULL
the	NULL
most	NULL
potent	NULL
region	NULL
localized	NULL
to	NULL
amino	NULL
acids	NULL
25	NULL
to	NULL
42	NULL
(	NULL
19	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
localization	NULL
of	NULL
the	NULL
domain	NULL
(	NULL
s	NULL
)	NULL
important	NULL
for	NULL
DNA	NULL
replication	NULL
is	NULL
not	NULL
as	NULL
clear	NULL
.	NULL

In	NULL
different	NULL
cell	NULL
types	NULL
there	NULL
are	NULL
distinct	NULL
portions	NULL
of	NULL
ZEBRA	NULL
required	NULL
for	NULL
DNA	NULL
replication	NULL
.	NULL

In	NULL
the	NULL
D98/HR1	NULL
cell	NULL
line	NULL
(	NULL
a	NULL
HeLa	NULL
cell	NULL
line	NULL
derivative	NULL
)	NULL
amino	NULL
acids	NULL
28	NULL
to	NULL
103	NULL
are	NULL
essential	NULL
for	NULL
DNA	NULL
replication	NULL
(	NULL
41	NULL
)	NULL
,	NULL
while	NULL
in	NULL
Vero	NULL
cells	NULL
(	NULL
an	NULL
African	NULL
green	NULL
monkey	NULL
cell	NULL
line	NULL
)	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
13	NULL
to	NULL
19	NULL
of	NULL
ZEBRA	NULL
abolishes	NULL
its	NULL
ability	NULL
to	NULL
support	NULL
replication	NULL
of	NULL
DNA	NULL
(	NULL
39	NULL
)	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
we	NULL
address	NULL
the	NULL
domain	NULL
requirements	NULL
of	NULL
ZEBRA	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
latently	NULL
infected	NULL
with	NULL
EBV	NULL
.	NULL

Previous	NULL
work	NULL
from	NULL
this	NULL
laboratory	NULL
has	NULL
shown	NULL
that	NULL
ZEBRA	NULL
's	NULL
activation	NULL
domain	NULL
can	NULL
be	NULL
replaced	NULL
by	NULL
potent	NULL
acidic	NULL
activation	NULL
regions	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Here	NULL
those	NULL
studies	NULL
are	NULL
extended	NULL
to	NULL
nonacidic	NULL
activation	NULL
domains	NULL
.	NULL

Heterologous	NULL
glutamine-rich	NULL
and	NULL
proline-rich	NULL
activation	NULL
domains	NULL
,	NULL
when	NULL
appended	NULL
to	NULL
a	NULL
ZEBRA	NULL
mutant	NULL
lacking	NULL
the	NULL
wild-type	NULL
activation	NULL
region	NULL
,	NULL
restored	NULL
its	NULL
capacity	NULL
to	NULL
induce	NULL
viral	NULL
early	NULL
antigen	NULL
and	NULL
to	NULL
stimulate	NULL
replication	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
EBV	NULL
origin	NULL
of	NULL
replication	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
deletion	NULL
analysis	NULL
of	NULL
ZEBRA	NULL
's	NULL
large	NULL
activation	NULL
region	NULL
indicated	NULL
that	NULL
no	NULL
subdomains	NULL
specific	NULL
for	NULL
early-antigen	NULL
induction	NULL
or	NULL
the	NULL
stimulation	NULL
of	NULL
lytic	NULL
replication	NULL
could	NULL
be	NULL
identified	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
ZEBRA	NULL
's	NULL
activation	NULL
domain	NULL
is	NULL
not	NULL
unique	NULL
and	NULL
can	NULL
be	NULL
replaced	NULL
by	NULL
heterologous	NULL
activation	NULL
domains	NULL
of	NULL
several	NULL
classes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
ZEBRA	NULL
's	NULL
ability	NULL
to	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
is	NULL
intimately	NULL
linked	NULL
to	NULL
both	NULL
its	NULL
role	NULL
as	NULL
an	NULL
in-ducer	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
and	NULL
its	NULL
role	NULL
as	NULL
an	NULL
essential	NULL
component	NULL
in	NULL
viral	NULL
lytic	NULL
replication	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

The	NULL
B-cell	NULL
lymphoma	NULL
lines	NULL
Clone	NULL
16	NULL
(	NULL
CL16	NULL
)	NULL
,	NULL
Raji	NULL
,	NULL
BL41/CL16	NULL
,	NULL
and	NULL
BJAB	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
8	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
antibiotics	NULL
at	NULL
37°C	NULL
under	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
atmosphere	NULL
(	NULL
4	NULL
)	NULL
.	NULL

CL16	NULL
cells	NULL
are	NULL
human	NULL
B	NULL
lymphocytes	NULL
which	NULL
harbor	NULL
the	NULL
nontransforming	NULL
P3HR-1	NULL
strain	NULL
of	NULL
EBV	NULL
in	NULL
the	NULL
latent	NULL
state	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Raji	NULL
cells	NULL
are	NULL
human	NULL
B	NULL
lymphocytes	NULL
which	NULL
contain	NULL
a	NULL
deleted	NULL
EBV	NULL
episome	NULL
that	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
carly	NULL
antigen	NULL
,	NULL
but	NULL
which	NULL
can	NULL
not	NULL
replicate	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
BLA41/CL16	NULL
cell	NULL
line	NULL
is	NULL
a	NULL
derivative	NULL
of	NULL
the	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
BL41	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
has	NULL
been	NULL
stably	NULL
infected	NULL
with	NULL
the	NULL
EBV	NULL
CL16	NULL
virus	NULL
.	NULL

After	NULL
prolonged	NULL
culture	NULL
in	NULL
vitro	NULL
,	NULL
the	NULL
EBV	NULL
in	NULL
BL41/CL16	NULL
cells	NULL
has	NULL
become	NULL
progressively	NULL
more	NULL
tightly	NULL
latent	NULL
and	NULL
can	NULL
no	NULL
longer	NULL
be	NULL
induced	NULL
by	NULL
6548	NULL
ASKOVIC	NULL
AND	NULL
BAUMANN	NULL
J.	NULL
ViRoL	NULL
.	NULL

1	NULL
167	NULL
245	NULL
ZEBRA	NULL
|	NULL
exon	NULL
I	NULL
|_exon	NULL
II	NULL
|_	NULL
exon	NULL
III	NULL
transactivation	NULL
DNA	NULL
binding	NULL
:	NULL
dimerization	NULL
100	NULL
25	NULL
141	NULL
227	NULL
za	NULL
|_I	NULL
|	NULL
|	NULL
1	NULL
[	NULL
{	NULL
P	NULL
T	NULL
m	NULL
]	NULL
131	NULL
227	NULL
Zdx	NULL
___	NULL
L	NULL
_T	NULL
G	NULL
T	NULL
i	NULL
]	NULL
100	NULL
25	NULL
141	NULL
227	NULL
400-479	NULL
z4vP	NULL
[	NULL
I	NULL
|	NULL
|_	NULL
1	NULL
T	NULL
GP	NULL
T	NULL
n	NULL
}	NULL
vP16	NULL
131	NULL
227	NULL
400-479	NULL
ZdxVF	NULL
|___31_T	NULL
On	NULL
_|	NULL
in	NULL
|	NULL
___	NULL
vig	NULL
___	NULL
]	NULL
100	NULL
25	NULL
141	NULL
227	NULL
ZdMquI'—	NULL
,	NULL
|	NULL
|	NULL
142-330	NULL
330	NULL
U	NULL
[	NULL
1	NULL
[	NULL
u	NULL
J	NULL
Meq	NULL
e	NULL
100	NULL
25	NULL
141	NULL
227	NULL
|	NULL
|	NULL
724-826	NULL
243C	NULL
|	NULL
1	NULL
|	NULL
_I	NULL
|_	NULL
I	NULL
EBNA3C	NULL
|	NULL
100	NULL
25	NULL
141	NULL
227	NULL
H	NULL
|	NULL
8	NULL
_	NULL
480-605	NULL
z0R	NULL
[	NULL
_	NULL
]	NULL
[	NULL
T	NULL
J	NULL
o	NULL
H	NULL
R	NULL
]	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
diagram	NULL
depicting	NULL
the	NULL
ZEBRA	NULL
chimeras	NULL
.	NULL

ZEBRA	NULL
's	NULL
exon	NULL
structure	NULL
is	NULL
shown	NULL
in	NULL
cDNA	NULL
form	NULL
at	NULL
the	NULL
top	NULL
of	NULL
the	NULL
diagram	NULL
.	NULL

Clone	NULL
designations	NULL
are	NULL
given	NULL
at	NULL
the	NULL
left	NULL
.	NULL

Numbers	NULL
above	NULL
each	NULL
diagram	NULL
represent	NULL
amino	NULL
acids	NULL
.	NULL

All	NULL
constructs	NULL
were	NULL
expressed	NULL
from	NULL
the	NULL
CMV	NULL
promoter	NULL
enhancer	NULL
element	NULL
in	NULL
a	NULL
derivative	NULL
of	NULL
vector	NULL
pHD1013	NULL
(	NULL
3	NULL
,	NULL
15	NULL
)	NULL
.	NULL

chemical	NULL
or	NULL
other	NULL
means	NULL
(	NULL
2	NULL
,	NULL
37	NULL
)	NULL
.	NULL

BJAB	NULL
is	NULL
an	NULL
EBV-negative	NULL
human	NULL
B-cell	NULL
line	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Electroporation	NULL
.	NULL

B-cell	NULL
lines	NULL
were	NULL
transfected	NULL
by	NULL
using	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
apparatus	NULL
with	NULL
a	NULL
capacitance	NULL
extender	NULL
,	NULL
at	NULL
960	NULL
wF	NULL
and	NULL
0.25	NULL
kV	NULL
in	NULL
0.4	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
.	NULL

After	NULL
electroporation	NULL
,	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
with	NULL
8	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
for	NULL
2	NULL
to	NULL
4	NULL
days	NULL
at	NULL
37°C	NULL
under	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Plasmid	NULL
constructs	NULL
.	NULL

The	NULL
Zd	NULL
clone	NULL
lacks	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
ZEBRA	NULL
.	NULL

It	NULL
contains	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
25	NULL
and	NULL
142	NULL
to	NULL
227	NULL
of	NULL
the	NULL
wild-type	NULL
ZEBRA	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
3	NULL
,	NULL
5	NULL
)	NULL
.	NULL

The	NULL
ZdVP	NULL
and	NULL
ZdR	NULL
clones	NULL
have	NULL
been	NULL
described	NULL
before	NULL
(	NULL
5	NULL
)	NULL
;	NULL
briefly	NULL
,	NULL
ZdVP	NULL
contains	NULL
amino	NULL
acids	NULL
400	NULL
to	NULL
479	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
's	NULL
VP16	NULL
protein	NULL
fused	NULL
to	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
Zd	NULL
,	NULL
and	NULL
ZdR	NULL
contains	NULL
amino	NULL
acids	NULL
480	NULL
to	NULL
605	NULL
of	NULL
EBV	NULL
's	NULL
R	NULL
protein	NULL
fused	NULL
to	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
Zd	NULL
.	NULL

The	NULL
Zd	NULL
chimeras	NULL
,	NULL
ZdMeq11339	NULL
and	NULL
Zd3C	NULL
,	NULL
contain	NULL
the	NULL
proline-rich	NULL
region	NULL
of	NULL
the	NULL
Marek	NULL
's	NULL
disease	NULL
virus	NULL
Meq	NULL
protein	NULL
(	NULL
amino	NULL
acids	NULL
142	NULL
to	NULL
339	NULL
)	NULL
(	NULL
35	NULL
)	NULL
and	NULL
the	NULL
glutamine-rich	NULL
region	NULL
of	NULL
EBV	NULL
's	NULL
EBNA3C	NULL
protein	NULL
(	NULL
amino	NULL
acids	NULL
724	NULL
to	NULL
826	NULL
)	NULL
(	NULL
32	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
Zdx	NULL
clone	NULL
contains	NULL
amino	NULL
acids	NULL
131	NULL
to	NULL
227	NULL
of	NULL
wild-type	NULL
ZEBRA	NULL
,	NULL
while	NULL
ZdxVP	NULL
contains	NULL
amino	NULL
acids	NULL
400	NULL
to	NULL
479	NULL
of	NULL
VP16	NULL
fused	NULL
to	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
Zdx	NULL
.	NULL

The	NULL
ZdMeq	NULL
deletions	NULL
were	NULL
generated	NULL
with	NULL
Bel	NULL
31	NULL
exonuclease	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Standard	NULL
cloning	NULL
techniques	NULL
were	NULL
used	NULL
to	NULL
generate	NULL
all	NULL
the	NULL
constructs	NULL
noted	NULL
here	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Where	NULL
necessary	NULL
,	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
double-stranded	NULL
DNA	NULL
sequencing	NULL
(	NULL
Sequenase	NULL
2	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

All	NULL
constructs	NULL
were	NULL
expressed	NULL
downstream	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
promoter	NULL
enhancer	NULL
in	NULL
a	NULL
derivative	NULL
of	NULL
the	NULL
expression	NULL
vector	NULL
pHD1013	NULL
(	NULL
3	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
ZEBRA	NULL
sequential	NULL
deletions	NULL
were	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
the	NULL
laboratory	NULL
of	NULL
M.	NULL
Carey	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
ZEBRA	NULL
internal	NULL
deletions	NULL
were	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
the	NULL
laboratory	NULL
of	NULL
E.	NULL
Flemington	NULL
(	NULL
18	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
liquid	NULL
phase	NULL
assay	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
separate	NULL
plasmids	NULL
containing	NULL
the	NULL
effector	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
and	NULL
the	NULL
target	NULL
(	NULL
5	NULL
mg	NULL
)	NULL
were	NULL
electroporated	NULL
into	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
10	NULL
x	NULL
10°	NULL
cells	NULL
.	NULL

Two	NULL
days	NULL
posttransfection	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
reaction	NULL
mixture	NULL
containing	NULL
0.25	NULL
Ci	NULL
of	NULL
[	NULL
*HJacetyl-coenzyme	NULL
A	NULL
(	NULL
Amersham	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
2	NULL
h.	NULL
After	NULL
incubation	NULL
*H-labelled	NULL
acetylated	NULL
chloramphenicol	NULL
was	NULL
extracted	NULL
with	NULL
toluene	NULL
and	NULL
quantitated	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

The	NULL
targets	NULL
used	NULL
were	NULL
EABSCAT	NULL
and	NULL
DPCAT	NULL
.	NULL

EABSCAT	NULL
contains	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
EBV	NULL
BMRF1	NULL
early	NULL
antigen	NULL
gene	NULL
(	NULL
EA-D	NULL
)	NULL
,	NULL
which	NULL
is	NULL
a	NULL
native	NULL
target	NULL
of	NULL
ZEBRA	NULL
(	NULL
26	NULL
)	NULL
.	NULL

DPCAT	NULL
contains	NULL
a	NULL
native	NULL
target	NULL
region	NULL
for	NULL
ZEBRA	NULL
which	NULL
includes	NULL
seven	NULL
ZREs	NULL
and	NULL
EBV	NULL
oriLyt	NULL
(	NULL
5	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Western	NULL
blots	NULL
.	NULL

Equal	NULL
numbers	NULL
of	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
10	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
electroporated	NULL
with	NULL
30	NULL
pg	NULL
of	NULL
each	NULL
plasmid	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
electroporation	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
protein	NULL
sample	NULL
buffer	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
were	NULL
resolved	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
through	NULL
10	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
and	NULL
subjected	NULL
to	NULL
immunoblot	NULL
analysis	NULL
.	NULL

Immunoblots	NULL
to	NULL
monitor	NULL
ZEBRA	NULL
expression	NULL
utilized	NULL
a	NULL
rabbit	NULL
anti-trpE	NULL
ZEBRA	NULL
exon	NULL
1	NULL
polyclonal	NULL
serum	NULL
(	NULL
1:7,500	NULL
in	NULL
15	NULL
%	NULL
dry	NULL
milk	NULL
)	NULL
as	NULL
the	NULL
primary	NULL
antiserum	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Immunoblots	NULL
to	NULL
monitor	NULL
early	NULL
antigen	NULL
utilized	NULL
a	NULL
mouse	NULL
anti-EA-D	NULL
monoclonal	NULL
antibody	NULL
(	NULL
1:10,000	NULL
in	NULL
10	NULL
%	NULL
dry	NULL
milk	NULL
;	NULL
Advanced	NULL
Biotechnologies	NULL
Inc.	NULL
)	NULL
as	NULL
the	NULL
primary	NULL
antiserum	NULL
.	NULL

Am	NULL
ersham	NULL
's	NULL
ECL	NULL
kit	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
secondary	NULL
antisera	NULL
,	NULL
was	NULL
used	NULL
for	NULL
immunoblot	NULL
detection	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
specifications	NULL
.	NULL

Replication	NULL
assays	NULL
.	NULL

Lymphocyte	NULL
origin	NULL
replication	NULL
(	NULL
LOR	NULL
)	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
effector	NULL
plasmid	NULL
(	NULL
30	NULL
mg	NULL
)	NULL
,	NULL
encoding	NULL
ZEBRA	NULL
or	NULL
a	NULL
ZEBRA	NULL
derivative	NULL
,	NULL
and	NULL
plasmid	NULL
p526	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
22	NULL
)	NULL
,	NULL
were	NULL
electroporated	NULL
into	NULL
CL16	NULL
cells	NULL
.	NULL

Four	NULL
days	NULL
posttransfection	NULL
,	NULL
total	NULL
DNA	NULL
was	NULL
isolated	NULL
and	NULL
digested	NULL
with	NULL
BamHI	NULL
to	NULL
linearize	NULL
the	NULL
vector	NULL
DNA	NULL
and	NULL
with	NULL
DpnI	NULL
to	NULL
detect	NULL
newly	NULL
replicated	NULL
plasmid	NULL
DNA	NULL
.	NULL

DpnI	NULL
cleavage	NULL
requires	NULL
that	NULL
DNA	NULL
be	NULL
methylated	NULL
at	NULL
adenine	NULL
residues	NULL
.	NULL

Adenine	NULL
methylation	NULL
occurs	NULL
in	NULL
Dam	NULL
*	NULL
bacteria	NULL
but	NULL
not	NULL
in	NULL
eukaryotes	NULL
.	NULL

Therefore	NULL
,	NULL
all	NULL
newly	NULL
replicated	NULL
p526	NULL
DNA	NULL
will	NULL
be	NULL
resistant	NULL
to	NULL
DprI	NULL
digestion	NULL
,	NULL
while	NULL
input	NULL
p526	NULL
DNA	NULL
(	NULL
which	NULL
was	NULL
grown	NULL
in	NULL
bacteria	NULL
)	NULL
will	NULL
be	NULL
sensitive	NULL
.	NULL

Control	NULL
plasmid	NULL
was	NULL
added	NULL
to	NULL
all	NULL
samples	NULL
prior	NULL
to	NULL
restriction	NULL
enzyme	NULL
digestion	NULL
to	NULL
ensure	NULL
that	NULL
cach	NULL
digest	NULL
was	NULL
complete	NULL
.	NULL

Samples	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
0.8	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
(	NULL
Hybond	NULL
N*	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
p526	NULL
plasmid	NULL
was	NULL
labelled	NULL
with	NULL
an	NULL
ECL	NULL
Southern	NULL
blot	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
and	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
for	NULL
hybridization	NULL
.	NULL

Following	NULL
hybridization	NULL
,	NULL
filters	NULL
were	NULL
washed	NULL
and	NULL
treated	NULL
with	NULL
chemiluminescent	NULL
reagents	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
specifications	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
(	NULL
exposure	NULL
,	NULL
1	NULL
to	NULL
30	NULL
min	NULL
}	NULL
.	NULL

Figure	NULL
preparation	NULL
.	NULL

All	NULL
autoradiograms	NULL
were	NULL
scanned	NULL
on	NULL
a	NULL
Hewlett-Packard	NULL
Scanjet	NULL
4C	NULL
scanner	NULL
with	NULL
Deskscan	NULL
II	NULL
software	NULL
at	NULL
a	NULL
resolution	NULL
of	NULL
900	NULL
dots/in	NULL
.	NULL

Images	NULL
were	NULL
saved	NULL
as	NULL
TIFF	NULL
files	NULL
and	NULL
imported	NULL
into	NULL
CorelDraw	NULL
5.0	NULL
for	NULL
annota-tion	NULL
.	NULL

Negatives	NULL
were	NULL
made	NULL
directly	NULL
from	NULL
CorelDraw	NULL
files	NULL
by	NULL
using	NULL
a	NULL
Management	NULL
Graphics	NULL
8XP	NULL
film	NULL
recorder	NULL
.	NULL

RESULTS	NULL
Small	NULL
internal	NULL
deletions	NULL
of	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
do	NULL
not	NULL
impair	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
latent	NULL
EBV	NULL
.	NULL

The	NULL
protein	NULL
sequences	NULL
responsible	NULL
for	NULL
ZEBRA	NULL
activation	NULL
have	NULL
been	NULL
mapped	NULL
to	NULL
amino	NULL
acids	NULL
25	NULL
to	NULL
152	NULL
by	NULL
reporter	NULL
gene	NULL
assays	NULL
.	NULL

Deletion	NULL
analysis	NULL
suggests	NULL
that	NULL
within	NULL
this	NULL
large	NULL
region	NULL
,	NULL
amino	NULL
acids	NULL
27	NULL
to	NULL
42	NULL
make	NULL
the	NULL
greatest	NULL
contribution	NULL
to	NULL
ZEBRA	NULL
's	NULL
activation	NULL
po-tency	NULL
.	NULL

However	NULL
,	NULL
previous	NULL
studies	NULL
have	NULL
not	NULL
addressed	NULL
the	NULL
capacity	NULL
of	NULL
various	NULL
ZEBRA	NULL
mutants	NULL
to	NULL
activate	NULL
gene	NULL
expression	NULL
directly	NULL
from	NULL
a	NULL
latent	NULL
viral	NULL
genome	NULL
and	NULL
to	NULL
disrupt	NULL
viral	NULL
latency	NULL
.	NULL

Here	NULL
,	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
if	NULL
subdomains	NULL
exist	NULL
within	NULL
the	NULL
diffuse	NULL
activation	NULL
region	NULL
of	NULL
ZEBRA	NULL
which	NULL
are	NULL
specific	NULL
in	NULL
determining	NULL
ZEBRA	NULL
's	NULL
ability	NULL
to	NULL
disrupt	NULL
latency	NULL
or	NULL
to	NULL
stimulate	NULL
EBV	NULL
lytic	NULL
replication	NULL
.	NULL

A	NULL
series	NULL
of	NULL
ZEBRA	NULL
constructs	NULL
bearing	NULL
sequential	NULL
25-amino-acid	NULL
internal	NULL
deletions	NULL
in	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
were	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
A	NULL
vlc	NULL
TATE	NULL
a	NULL
Raji	NULL
cells	NULL
amiss	NULL
|	NULL
same	NULL
|Trmoe	NULL
a	NULL
EA-D	NULL
s.	NULL
J	NULL
«	NULL
atte	NULL
fH	NULL
?	NULL

I	NULL
3	NULL
|	NULL
4	NULL
|	NULL
s	NULL
[	NULL
s	NULL
IHG	NULL
I	NULL
8	NULL
B	NULL
U	NULL
zr	NULL
|a	NULL
|a	NULL
|	NULL
za	NULL
|	NULL
2	NULL
|	NULL
z	NULL
Raji	NULL
cells	NULL
amiss	NULL
|	NULL
sare	NULL
|	NULL
rrnos	NULL
a	NULL
ZEBRA	NULL
``	NULL
Cs..	NULL
_	NULL
<	NULL
mese	NULL
l	NULL
avuipcaupuenauagdt	NULL
ZA	NULL
ZA	NULL
ZA	NULL
ZA	NULL
ZA	NULL
CL16	NULL
cells	NULL
27/53	NULL
|	NULL
52778	NULL
17703	NULL
1027128	NULL
127/153	NULL
a	NULL
EA-D	NULL
DE	NULL
a	NULL
cm	NULL
-	NULL
»	NULL
1	NULL
]	NULL
2|3	NULL
]	NULL
4	NULL
[	NULL
5	NULL
]	NULL
6|7|8	NULL
Zd	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
small	NULL
internal	NULL
deletions	NULL
in	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
on	NULL
ZEBRA	NULL
function	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
EA-D	NULL
induction	NULL
in	NULL
Raji	NULL
cells	NULL
by	NULL
ZEBRA	NULL
internal-deletion	NULL
mutants	NULL
.	NULL

Cells	NULL
were	NULL
electroporated	NULL
with	NULL
30	NULL
mg	NULL
of	NULL
each	NULL
construct	NULL
and	NULL
harvested	NULL
in	NULL
protein	NULL
sample	NULL
buffer	NULL
3	NULL
days	NULL
after	NULL
transfection	NULL
.	NULL

Protein	NULL
samples	NULL
(	NULL
equivalents	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
elec-trophoretically	NULL
to	NULL
a	NULL
nitrocellulose	NULL
filter	NULL
.	NULL

Primary	NULL
immunoblot	NULL
analysis	NULL
on	NULL
the	NULL
filter	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
EA-D	NULL
(	NULL
a	NULL
EA-D	NULL
;	NULL
Advanced	NULL
Biotechnologies	NULL
)	NULL
.	NULL

The	NULL
bands	NULL
were	NULL
visualized	NULL
with	NULL
a	NULL
goat	NULL
antimouse	NULL
monoclonal	NULL
antibody	NULL
as	NULL
the	NULL
secondary	NULL
antibody	NULL
and	NULL
with	NULL
an	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
ZEBRA	NULL
internal-deletion	NULL
mutants	NULL
are	NULL
designated	NULL
by	NULL
the	NULL
amino	NULL
acids	NULL
that	NULL
have	NULL
been	NULL
deleted	NULL
from	NULL
wild-type	NULL
ZEBRA	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
ZA	NULL
27/53	NULL
lacks	NULL
amino	NULL
acids	NULL
27	NULL
to	NULL
53	NULL
)	NULL
.	NULL

Lane	NULL
V	NULL
,	NULL
vector	NULL
;	NULL
lane	NULL
Z	NULL
,	NULL
ZEBRA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Expression	NULL
of	NULL
ZEBRA	NULL
internal	NULL
deletions	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Samples	NULL
were	NULL
processed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
panel	NULL
A	NULL
and	NULL
subjected	NULL
to	NULL
immunoblot	NULL
analysis	NULL
with	NULL
a	NULL
rabbit	NULL
anti-ZEBRA	NULL
exon	NULL
1	NULL
polyclonal	NULL
antiserum	NULL
(	NULL
«	NULL
ZEBRA	NULL
)	NULL
as	NULL
the	NULL
primary	NULL
antibody	NULL
(	NULL
43	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
EA-D	NULL
induction	NULL
by	NULL
ZEBRA	NULL
internal	NULL
deletion	NULL
mutants	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

The	NULL
procedures	NULL
employed	NULL
were	NULL
the	NULL
same	NULL
as	NULL
those	NULL
described	NULL
for	NULL
panel	NULL
A.	NULL
tested	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
initiate	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
capacity	NULL
to	NULL
induce	NULL
early	NULL
antigen-diffuse	NULL
(	NULL
EA-D	NULL
)	NULL
expression	NULL
.	NULL

EA-D	NULL
expression	NULL
is	NULL
a	NULL
marker	NULL
of	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
and	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
since	NULL
early-antigen	NULL
expression	NULL
does	NULL
not	NULL
occur	NULL
during	NULL
latent	NULL
EBV	NULL
infection	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
EA-D	NULL
promoter	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
responsive	NULL
to	NULL
ZEBRA	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Each	NULL
clone	NULL
was	NULL
electroporated	NULL
in	NULL
30-pg	NULL
amounts	NULL
into	NULL
EBV-positive	NULL
Raji	NULL
cells	NULL
,	NULL
and	NULL
EA-D	NULL
expression	NULL
was	NULL
assessed	NULL
by	NULL
immunoblot	NULL
analysis	NULL
3	NULL
days	NULL
later	NULL
.	NULL

All	NULL
five	NULL
constructs	NULL
with	NULL
internal	NULL
deletions	NULL
of	NULL
ZEBRA	NULL
induced	NULL
early-antigen	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
7	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
vector	NULL
without	NULL
an	NULL
insert	NULL
and	NULL
Zd	NULL
(	NULL
ZEBRA	NULL
without	NULL
an	NULL
activation	NULL
domain	NULL
)	NULL
failed	NULL
to	NULL
induce	NULL
EA-D	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
all	NULL
constructs	NULL
were	NULL
abundantly	NULL
expressed	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

EA-D	NULL
induction	NULL
was	NULL
also	NULL
tested	NULL
in	NULL
the	NULL
CL16	NULL
B-cell	NULL
line	NULL
and	NULL
shown	NULL
to	NULL
be	NULL
identical	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
pattern	NULL
of	NULL
early-antigen	NULL
induction	NULL
is	NULL
reproducible	NULL
and	NULL
is	NULL
not	NULL
unique	NULL
to	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
early-antigen	NULL
assay	NULL
tests	NULL
the	NULL
ability	NULL
of	NULL
each	NULL
ZEBRA	NULL
deletion	NULL
mutant	NULL
to	NULL
induce	NULL
expression	NULL
of	NULL
a	NULL
single	NULL
protein	NULL
from	NULL
DISRUPTION	NULL
OF	NULL
EBV	NULL
LATENCY	NULL
BY	NULL
ZEBRA	NULL
-	NULL
6549	NULL
the	NULL
EBV	NULL
genome	NULL
.	NULL

A	NULL
more	NULL
stringent	NULL
functional	NULL
assay	NULL
of	NULL
these	NULL
mutants	NULL
is	NULL
to	NULL
test	NULL
their	NULL
ability	NULL
to	NULL
stimulate	NULL
lytic	NULL
replication	NULL
,	NULL
because	NULL
this	NULL
requires	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
at	NULL
least	NULL
seven	NULL
EBV	NULL
proteins	NULL
which	NULL
are	NULL
essential	NULL
for	NULL
EBV	NULL
origin	NULL
replication	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
LOR	NULL
assay	NULL
was	NULL
used	NULL
to	NULL
test	NULL
the	NULL
five	NULL
ZEBRA	NULL
internal-deletion	NULL
mutants	NULL
.	NULL

Thirty	NULL
micrograms	NULL
of	NULL
each	NULL
construct	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
p526	NULL
plasmid	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
EBV	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
22	NULL
)	NULL
,	NULL
were	NULL
electroporated	NULL
into	NULL
EBV-positive	NULL
CL16	NULL
cells	NULL
.	NULL

Four	NULL
days	NULL
posttransfection	NULL
,	NULL
samples	NULL
were	NULL
tested	NULL
for	NULL
p526	NULL
replication	NULL
by	NULL
Southern	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
EA-D	NULL
analysis	NULL
,	NULL
all	NULL
five	NULL
ZEBRA	NULL
internal-deletion	NULL
constructs	NULL
were	NULL
active	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
8	NULL
)	NULL
.	NULL

The	NULL
ZEBRA	NULL
internal	NULL
deletions	NULL
were	NULL
also	NULL
tested	NULL
in	NULL
reporter	NULL
gene	NULL
assays	NULL
to	NULL
determine	NULL
if	NULL
their	NULL
capacity	NULL
to	NULL
transcriptionally	NULL
activate	NULL
specific	NULL
targets	NULL
mirrored	NULL
their	NULL
ability	NULL
to	NULL
function	NULL
in	NULL
the	NULL
EA-D	NULL
induction	NULL
and	NULL
the	NULL
LOR	NULL
bioassays	NULL
.	NULL

EABSCAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
EA-D	NULL
gene	NULL
,	NULL
was	NULL
assayed	NULL
in	NULL
Raji	NULL
cells	NULL
,	NULL
and	NULL
DPCAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
BHRF1	NULL
gene	NULL
,	NULL
included	NULL
within	NULL
the	NULL
oriLyt	NULL
region	NULL
,	NULL
was	NULL
assayed	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

These	NULL
two	NULL
targets	NULL
were	NULL
selected	NULL
for	NULL
reporter	NULL
gene	NULL
A	NULL
v	NULL
U	NULL
o	NULL
z	NULL
»	NULL
|	NULL
m	NULL
|	NULL
zm	NULL
|	NULL
m	NULL
|	NULL
2	NULL
|	NULL
;	NULL
-Dpnl	NULL
27/53	NULL
|	NULL
Sare	NULL
|	NULL
77/103	NULL
[	NULL
1027128127153	NULL
CL16	NULL
cells	NULL
LOR	NULL
assay	NULL
wap	NULL
uw	NULL
)	NULL
.-	NULL
.	NULL

UJ	NULL
-	NULL
--	NULL
uas	NULL
suilp	NULL
>	NULL
|	NULL
Wh	NULL
-	NULL
gay	NULL
aas	NULL
tt	NULL
*	NULL
want	NULL
uy	NULL
-	NULL
w	NULL
wath	NULL
wit	NULL
**	NULL
l	NULL
cee	NULL
gee	NULL
g	NULL
«	NULL
aan	NULL
fei	NULL
user	NULL
«	NULL
ou	NULL
pwt	NULL
a	NULL
L	NULL
®	NULL
1|213|4l5|617|8l9	NULL
B	NULL
za	NULL
|	NULL
zm	NULL
|	NULL
za	NULL
|	NULL
z	NULL
|	NULL
za	NULL
v	NULL
Z	NULL
|	NULL
amiss	NULL
|	NULL
same	NULL
|	NULL
roa	NULL
|roanzshiarnsa|	NULL
20	NULL
CAT	NULL
assay	NULL
Expscat	NULL
(	NULL
Raji	NULL
cells	NULL
)	NULL
|	NULL
1	NULL
.	NULL

[	NULL
216.5	NULL
|	NULL
88.0	NULL
|	NULL
49.4	NULL
|	NULL
114.8	NULL
|	NULL
183.6	NULL
|	NULL
184.4	NULL
]	NULL
1.5	NULL
DPGAT	NULL
(	NULL
CL16	NULL
cells	NULL
)	NULL
]	NULL
1	NULL
|	NULL
34.5	NULL
|	NULL
76.2	NULL
|	NULL
68.6	NULL
|	NULL
38.5	NULL
|	NULL
73.7	NULL
|	NULL
s4.0	NULL
|	NULL
1.7	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
small	NULL
internal	NULL
deletions	NULL
in	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
on	NULL
its	NULL
function	NULL
.	NULL

(	NULL
A	NULL
)	NULL
LOR	NULL
analysis	NULL
of	NULL
the	NULL
ZEBRA	NULL
internal-deletion	NULL
clones	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
electroporated	NULL
and	NULL
processed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

DNA	NULL
was	NULL
isolated	NULL
from	NULL
each	NULL
transfected	NULL
sample	NULL
,	NULL
and	NULL
the	NULL
equivalent	NULL
of	NULL
0.8	NULL
X	NULL
10°	NULL
cells	NULL
was	NULL
digested	NULL
with	NULL
DprI	NULL
and	NULL
BamHI	NULL
(	NULL
with	NULL
BamHI	NULL
only	NULL
in	NULL
the	NULL
first	NULL
lane	NULL
)	NULL
and	NULL
subjected	NULL
to	NULL
Southern	NULL
blot	NULL
analysis	NULL
with	NULL
a	NULL
chemiluminescence	NULL
detection	NULL
kit	NULL
(	NULL
ECL	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

Plasmid	NULL
p526	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

For	NULL
demonstration	NULL
purposes	NULL
the	NULL
complete	NULL
blot	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
upper	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
linearized	NULL
p526	NULL
.	NULL

The	NULL
lower	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
control	NULL
plasmid	NULL
incorporated	NULL
into	NULL
all	NULL
samples	NULL
to	NULL
monitor	NULL
for	NULL
complete	NULL
digestion	NULL
.	NULL

Lanes	NULL
are	NULL
as	NULL
explained	NULL
in	NULL
the	NULL
Fig	NULL
.	NULL

2	NULL
legend	NULL
.	NULL

The	NULL
faster-migrating	NULL
bands	NULL
present	NULL
in	NULL
lanes	NULL
2	NULL
to	NULL
9	NULL
are	NULL
DpnI	NULL
digestion	NULL
products	NULL
of	NULL
unreplicated	NULL
input	NULL
plasmid	NULL
DNA	NULL
,	NULL
which	NULL
are	NULL
expected	NULL
from	NULL
this	NULL
type	NULL
of	NULL
analysis	NULL
.	NULL

For	NULL
simplicity	NULL
,	NULL
subsequent	NULL
figures	NULL
depicting	NULL
LOR	NULL
assay	NULL
results	NULL
will	NULL
display	NULL
only	NULL
the	NULL
pertinent	NULL
upper	NULL
replicated	NULL
band	NULL
and	NULL
the	NULL
control	NULL
band	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Reporter	NULL
gene	NULL
assays	NULL
of	NULL
the	NULL
internal-deletion	NULL
mutants	NULL
.	NULL

The	NULL
target	NULL
EABSCAT	NULL
was	NULL
used	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
target	NULL
DPCAT	NULL
was	NULL
used	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

Numbers	NULL
indicate	NULL
fold	NULL
activation	NULL
relative	NULL
to	NULL
the	NULL
CMV	NULL
vector	NULL
(	NULL
V	NULL
)	NULL
,	NULL
which	NULL
was	NULL
taken	NULL
to	NULL
be	NULL
1.0	NULL
.	NULL

Each	NULL
number	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

6550	NULL
_	NULL
ASKOVIC	NULL
AND	NULL
BAUMANN	NULL
v	NULL
|	NULL
Z	NULL
[	NULL
Z2	NULL
]	NULL
Z2	NULL
]	NULL
2	NULL
]	NULL
Z2	NULL
]	NULL
Z	NULL
Raji	NULL
cells	NULL
2	NULL
|	NULL
25	NULL
|	NULL
51	NULL
|	NULL
77	NULL
|	NULL
99	NULL
|	NULL
131	NULL
a	NULL
EA-D	NULL
I|	NULL
1	NULL
T2	NULL
TB	NULL
TAT	NULL
s	NULL
|	NULL
s	NULL
IC	NULL
B	NULL
vol	NULL
y	NULL
[	NULL
2	NULL
]	NULL
z	NULL
|	NULL
2	NULL
|	NULL
2	NULL
|	NULL
2	NULL
|	NULL
z	NULL
-DpnI	NULL
2	NULL
25	NULL
|	NULL
51	NULL
77	NULL
|	NULL
99	NULL
|	NULL
131	NULL
CL16	NULL
cells	NULL
LOR	NULL
assay	NULL
&	NULL
©	NULL
aw	NULL
-	NULL
»	NULL
|	NULL
&	NULL
_	NULL
1	NULL
[	NULL
2	NULL
[	NULL
T3	NULL
T4	NULL
ITs	NULL
[	NULL
s	NULL
]	NULL
Ts	NULL
M	NULL
Z	NULL
Z	NULL
Z	NULL
Z	NULL
Z	NULL
z	NULL
2	NULL
25	NULL
|	NULL
51	NULL
|	NULL
77	NULL
|	NULL
99	NULL
|	NULL
131	NULL
CAT	NULL
assay	NULL
\	NULL
-==-	NULL
(	NULL
Raj	NULL
cells	NULL
|	NULL
1	NULL
[	NULL
91.7	NULL
98.0	NULL
]	NULL
81	NULL
|	NULL
14	NULL
|	NULL
1.3	NULL
|	NULL
1.0	NULL
DPCAT	NULL
(	NULL
Cib	NULL
carg|	NULL
1	NULL
.	NULL

[	NULL
27.8	NULL
|	NULL
23.4	NULL
]	NULL
1.4	NULL
|	NULL
11	NULL
|	NULL
0.7	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Evaluation	NULL
of	NULL
progressive	NULL
deletions	NULL
of	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
EA-D	NULL
induction	NULL
by	NULL
ZEBRA	NULL
deletion	NULL
mutants	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
by	NULL
using	NULL
the	NULL
Western	NULL
blot	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
specifications	NULL
and	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2A	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Induction	NULL
of	NULL
replication	NULL
of	NULL
the	NULL
p526	NULL
plasmid	NULL
in	NULL
CL16	NULL
cells	NULL
(	NULL
LOR	NULL
assay	NULL
)	NULL
by	NULL
the	NULL
ZEBRA	NULL
deletion	NULL
mutants	NULL
.	NULL

Southern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

V	NULL
,	NULL
vector	NULL
.	NULL

In	NULL
lane	NULL
1	NULL
no	NULL
DprI	NULL
enzyme	NULL
was	NULL
added	NULL
.	NULL

Clones	NULL
are	NULL
designated	NULL
by	NULL
initial	NULL
amino	NULL
acid	NULL
,	NULL
with	NULL
all	NULL
clones	NULL
ending	NULL
with	NULL
amino	NULL
acid	NULL
245	NULL
;	NULL
for	NULL
example	NULL
,	NULL
Z2	NULL
denotes	NULL
ZEBRA	NULL
amino	NULL
acids	NULL
2	NULL
to	NULL
245	NULL
.	NULL

The	NULL
upper	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
linearized	NULL
p526	NULL
.	NULL

The	NULL
lower	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
control	NULL
plasmid	NULL
incorporated	NULL
into	NULL
all	NULL
samples	NULL
to	NULL
monitor	NULL
for	NULL
complete	NULL
digestion	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Reporter	NULL
gene	NULL
analysis	NULL
of	NULL
the	NULL
ZEBRA	NULL
progressive	NULL
deletion	NULL
mutants	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
as	NULL
explained	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

assays	NULL
because	NULL
they	NULL
match	NULL
the	NULL
promoter	NULL
regions	NULL
tested	NULL
in	NULL
the	NULL
bioassays	NULL
employed	NULL
in	NULL
these	NULL
studies	NULL
and	NULL
might	NULL
therefore	NULL
provide	NULL
a	NULL
more	NULL
relevant	NULL
standard	NULL
for	NULL
comparison	NULL
.	NULL

Again	NULL
,	NULL
all	NULL
five	NULL
clones	NULL
were	NULL
active	NULL
in	NULL
the	NULL
CAT	NULL
assay	NULL
independent	NULL
of	NULL
the	NULL
target	NULL
or	NULL
the	NULL
cell	NULL
line	NULL
employed	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
small	NULL
deletions	NULL
in	NULL
the	NULL
ZEBRA	NULL
activation	NULL
region	NULL
do	NULL
not	NULL
destroy	NULL
its	NULL
ability	NULL
to	NULL
disrupt	NULL
latency	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
distinct	NULL
subdomain	NULL
that	NULL
was	NULL
required	NULL
specifically	NULL
for	NULL
transcriptional	NULL
activation	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
early	NULL
antigen	NULL
,	NULL
or	NULL
the	NULL
stimulation	NULL
of	NULL
lytic	NULL
replication	NULL
could	NULL
be	NULL
identified	NULL
.	NULL

The	NULL
amino-terminal	NULL
50	NULL
amino	NULL
acids	NULL
of	NULL
ZEBRA	NULL
are	NULL
required	NULL
for	NULL
latency	NULL
disruption	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
region	NULL
required	NULL
for	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
,	NULL
ZEBRA	NULL
mutants	NULL
with	NULL
progressive	NULL
deletions	NULL
from	NULL
the	NULL
amino-terminal	NULL
end	NULL
were	NULL
tested	NULL
for	NULL
activity	NULL
.	NULL

The	NULL
clones	NULL
are	NULL
designated	NULL
by	NULL
the	NULL
initial	NULL
amino	NULL
acid	NULL
retained	NULL
from	NULL
wild-type	NULL
ZEBRA	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
Z	NULL
(	NULL
2	NULL
)	NULL
contains	NULL
amino	NULL
acids	NULL
2	NULL
to	NULL
245	NULL
of	NULL
ZEBRA	NULL
]	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Clones	NULL
were	NULL
first	NULL
assayed	NULL
to	NULL
determine	NULL
their	NULL
capacity	NULL
to	NULL
induce	NULL
EBV	NULL
early	NULL
antigen	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
to	NULL
induce	NULL
EA-D	NULL
was	NULL
lost	NULL
in	NULL
construct	NULL
Z	NULL
(	NULL
51	NULL
)	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
first	NULL
50	NULL
amino	NULL
acids	NULL
of	NULL
ZEBRA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
but	NULL
EA-D	NULL
induction	NULL
was	NULL
retained	NULL
by	NULL
clones	NULL
Z	NULL
(	NULL
2	NULL
)	NULL
and	NULL
Z	NULL
(	NULL
25	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

When	NULL
tested	NULL
by	NULL
immunoblot	NULL
analysis	NULL
,	NULL
all	NULL
clones	NULL
were	NULL
found	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
abundance	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
pattern	NULL
of	NULL
EA-D	NULL
induction	NULL
was	NULL
identical	NULL
in	NULL
CL16	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
deletion	NULL
mutants	NULL
were	NULL
next	NULL
tested	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
Z	NULL
(	NULL
2	NULL
)	NULL
and	NULL
Z	NULL
(	NULL
25	NULL
)	NULL
,	NULL
Z	NULL
(	NULL
51	NULL
)	NULL
was	NULL
also	NULL
able	NULL
to	NULL
induce	NULL
replication	NULL
of	NULL
the	NULL
p526	NULL
plasmid	NULL
containing	NULL
the	NULL
EBV	NULL
orilyt	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
,	NULL
albeit	NULL
at	NULL
a	NULL
reduced	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
3	NULL
through	NULL
5	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
using	NULL
DPCAT	NULL
(	NULL
orilLyt	NULL
promoter	NULL
region	NULL
)	NULL
and	NULL
EABSCAT	NULL
(	NULL
EA	NULL
promoter	NULL
)	NULL
as	NULL
targets	NULL
J.	NULL
ViRoL	NULL
.	NULL

supported	NULL
results	NULL
obtained	NULL
with	NULL
the	NULL
LOR	NULL
and	NULL
EA-D	NULL
bioassays	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Notably	NULL
,	NULL
activation	NULL
was	NULL
apparent	NULL
with	NULL
the	NULL
Z	NULL
(	NULL
51	NULL
)	NULL
construct	NULL
on	NULL
DPCAT	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
results	NULL
obtained	NULL
with	NULL
this	NULL
construct	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
Z	NULL
(	NULL
51	NULL
)	NULL
in	NULL
the	NULL
orilLyt	NULL
assay	NULL
reflects	NULL
the	NULL
increased	NULL
sensitivity	NULL
of	NULL
this	NULL
assay	NULL
over	NULL
EA-D	NULL
analysis	NULL
.	NULL

Similarly	NULL
,	NULL
DPCAT	NULL
contains	NULL
an	NULL
excellent	NULL
promoter	NULL
target	NULL
for	NULL
ZEBRA	NULL
,	NULL
the	NULL
oriLyt	NULL
region	NULL
,	NULL
which	NULL
harbors	NULL
seven	NULL
ZREs	NULL
and	NULL
is	NULL
highly	NULL
sensitive	NULL
to	NULL
ZEBRA	NULL
activation	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
first	NULL
25	NULL
amino	NULL
acids	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
ability	NULL
of	NULL
ZEBRA	NULL
to	NULL
function	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
in	NULL
any	NULL
of	NULL
the	NULL
assays	NULL
used	NULL
here	NULL
.	NULL

These	NULL
results	NULL
were	NULL
of	NULL
interest	NULL
because	NULL
a	NULL
recent	NULL
report	NULL
has	NULL
shown	NULL
that	NULL
deletion	NULL
of	NULL
amino	NULL
acids	NULL
13	NULL
to	NULL
19	NULL
of	NULL
ZEBRA	NULL
abolishes	NULL
its	NULL
ability	NULL
to	NULL
induce	NULL
viral	NULL
DNA	NULL
replication	NULL
in	NULL
Vero	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Nonacidic	NULL
activation	NULL
domains	NULL
can	NULL
substitute	NULL
for	NULL
ZEBRA	NULL
's	NULL
activation	NULL
domain	NULL
.	NULL

If	NULL
,	NULL
as	NULL
the	NULL
above	NULL
data	NULL
suggests	NULL
,	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
functions	NULL
as	NULL
a	NULL
unit	NULL
without	NULL
subdomains	NULL
,	NULL
then	NULL
other	NULL
discrete	NULL
activation	NULL
domains	NULL
may	NULL
be	NULL
able	NULL
to	NULL
completely	NULL
substitute	NULL
for	NULL
its	NULL
activity	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
this	NULL
,	NULL
this	NULL
laboratory	NULL
has	NULL
previously	NULL
demonstrated	NULL
that	NULL
potent	NULL
acidic	NULL
activation	NULL
domains	NULL
can	NULL
replace	NULL
the	NULL
ZEBRA	NULL
activation	NULL
region	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
two	NULL
nonacidic	NULL
activation	NULL
domains	NULL
,	NULL
the	NULL
glutamine-rich	NULL
domain	NULL
of	NULL
the	NULL
EBV	NULL
EBNA	NULL
3C	NULL
protein	NULL
and	NULL
the	NULL
proline-rich	NULL
domain	NULL
of	NULL
the	NULL
Marek	NULL
's	NULL
disease	NULL
virus	NULL
Meq	NULL
protein	NULL
,	NULL
were	NULL
fused	NULL
to	NULL
a	NULL
ZEBRA	NULL
mutant	NULL
which	NULL
lacks	NULL
an	NULL
activation	NULL
domain	NULL
(	NULL
Zd	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
Zd3C	NULL
and	NULL
ZdMeqII339	NULL
chimeras	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
were	NULL
first	NULL
tested	NULL
for	NULL
the	NULL
capacity	NULL
to	NULL
initiate	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
EA-D	NULL
expression	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

When	NULL
compared	NULL
to	NULL
the	NULL
potent	NULL
acidic	NULL
Zd	NULL
chimeras	NULL
,	NULL
ZdVP	NULL
and	NULL
ZdR	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
7	NULL
)	NULL
,	NULL
the	NULL
nonacidic	NULL
chimeras	NULL
were	NULL
found	NULL
to	NULL
be	NULL
equally	NULL
effective	NULL
at	NULL
Zd	NULL
Meql	NULL
!	NULL

VP	NULL
I	NULL
339I	NULL
3C	NULL
I	NULL
R	NULL
Raji	NULL
cells	NULL
a	NULL
EA-D	NULL
B	NULL
120	NULL
Raji	NULL
cells	NULL
110	NULL
1	NULL
VECTOR	NULL
EABSCAT	NULL
_	NULL
199	NULL
|	NULL
2	NULL
ZEBRA	NULL
oo	NULL
|	NULL
32d	NULL
a	NULL
4	NULL
ZdVP	NULL
€	NULL
59	NULL
|	NULL
52d	NULL
Meq1339	NULL
§	NULL
70	NULL
|	NULL
62430	NULL
@	NULL
60	NULL
|	NULL
7ZdR	NULL
g	NULL
50	NULL
E	NULL
40	NULL
ZA	NULL
=1.0	NULL
§	NULL
so	NULL
&	NULL
20	NULL
o	NULL
10	NULL
w	NULL
[	NULL
l	NULL
ill	NULL
8	NULL
)	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Analysis	NULL
of	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
substitution	NULL
constructs	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EA-D	NULL
induction	NULL
by	NULL
ZEBRA	NULL
chimeric	NULL
clones	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Electroporation	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2A	NULL
.	NULL

V	NULL
,	NULL
vector	NULL
;	NULL
Z	NULL
,	NULL
ZEBRA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Reporter	NULL
gene	NULL
analysis	NULL
of	NULL
ZEBRA	NULL
chimeric	NULL
constructs	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
target	NULL
employed	NULL
was	NULL
EABSCAT	NULL
.	NULL

Fold	NULL
activation	NULL
relative	NULL
to	NULL
Zd	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
arbitrarily	NULL
taken	NULL
to	NULL
be	NULL
1.0-fold	NULL
,	NULL
is	NULL
given	NULL
on	NULL
the	NULL
vertical	NULL
axis	NULL
.	NULL

Clone	NULL
designations	NULL
are	NULL
shown	NULL
within	NULL
the	NULL
figure	NULL
.	NULL

Results	NULL
are	NULL
averages	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
,	NULL
and	NULL
error	NULL
bars	NULL
indicate	NULL
1	NULL
standard	NULL
deviation	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
CL16	NULL
cells	NULL
LOR	NULL
assay	NULL
18	NULL
rt	NULL
1	NULL
vEctoR	NULL
B	NULL
is	NULL
|	NULL
2	NULL
ZEBRA	NULL
3	NULL
2d	NULL
Zd	NULL
=	NULL
1.0	NULL
CL16	NULL
cells	NULL
14	NULL
|	NULL
4	NULL
ZaVvP	NULL
DPCAT	NULL
5	NULL
ZdR	NULL
®	NULL
12	NULL
6	NULL
243C	NULL
-	NULL
7	NULL
ZdMeql1339	NULL
10	NULL
®	NULL
g	NULL
.	NULL

>	NULL
6	NULL
4	NULL
2	NULL
I	NULL
o	NULL
|	NULL
_	NULL
mim	NULL
|__|	NULL
10	NULL
2	NULL
3	NULL
40	NULL
50060	NULL
7	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
ZEBRA	NULL
chimeras	NULL
.	NULL

(	NULL
A	NULL
)	NULL
oriLyt	NULL
analysis	NULL
of	NULL
the	NULL
ZEBRA	NULL
chimeras	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

oriLyt	NULL
analysis	NULL
was	NULL
conducted	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

The	NULL
upper	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
linearized	NULL
p526	NULL
.	NULL

The	NULL
lower	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
control	NULL
plasmid	NULL
incorporated	NULL
into	NULL
all	NULL
samples	NULL
to	NULL
monitor	NULL
for	NULL
complete	NULL
digestion	NULL
.	NULL

V	NULL
,	NULL
vector	NULL
;	NULL
Z	NULL
,	NULL
ZEBRA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Activation	NULL
of	NULL
the	NULL
DPCAT	NULL
target	NULL
by	NULL
the	NULL
ZEBRA	NULL
chimeras	NULL
.	NULL

DPCAT	NULL
contains	NULL
the	NULL
EBV	NULL
oriLyt	NULL
region	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
as	NULL
explained	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5B	NULL
.	NULL

CAT	NULL
activity	NULL
(	NULL
relative	NULL
activation	NULL
)	NULL
inducing	NULL
EA-D	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
CL16	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
the	NULL
nonacidic	NULL
Zd	NULL
chimeras	NULL
were	NULL
assayed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
EA-D	NULL
promoter	NULL
from	NULL
the	NULL
reporter	NULL
gene	NULL
construct	NULL
EABSCAT	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
columns	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Both	NULL
constructs	NULL
display	NULL
activation	NULL
ability	NULL
in	NULL
Raji	NULL
cells	NULL
which	NULL
is	NULL
similar	NULL
in	NULL
magnitude	NULL
to	NULL
that	NULL
seen	NULL
for	NULL
the	NULL
potent	NULL
acidic	NULL
activation	NULL
constructs	NULL
ZdVP	NULL
and	NULL
ZdR	NULL
.	NULL

Furthermore	NULL
,	NULL
immunoblot	NULL
analysis	NULL
indicated	NULL
that	NULL
all	NULL
constructs	NULL
were	NULL
abundantly	NULL
expressed	NULL
(	NULL
2	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
demonstrate	NULL
that	NULL
nonacidic	NULL
activation	NULL
domains	NULL
can	NULL
restore	NULL
Zd	NULL
's	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
EA-D	NULL
promoter	NULL
both	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
intact	NULL
viral	NULL
genome	NULL
and	NULL
in	NULL
the	NULL
context	NULL
of	NULL
a	NULL
plasmid	NULL
construct	NULL
independent	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
since	NULL
expression	NULL
of	NULL
EA-D	NULL
is	NULL
a	NULL
marker	NULL
for	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
,	NULL
these	NULL
experiments	NULL
also	NULL
suggest	NULL
that	NULL
the	NULL
ZEBRA	NULL
chimeras	NULL
can	NULL
initiate	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
.	NULL

Zd3C	NULL
and	NULL
were	NULL
also	NULL
subjected	NULL
to	NULL
the	NULL
more	NULL
stringent	NULL
LOR	NULL
assay	NULL
,	NULL
which	NULL
tests	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
full	NULL
repertoire	NULL
of	NULL
gene	NULL
products	NULL
necessary	NULL
for	NULL
lytic	NULL
viral	NULL
replication	NULL
.	NULL

Constructs	NULL
were	NULL
electroporated	NULL
into	NULL
EBV-positive	NULL
CL16	NULL
cells	NULL
along	NULL
with	NULL
the	NULL
p526	NULL
plasmid	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
EBV	NULL
orilLyt	NULL
.	NULL

Southern	NULL
blot	NULL
analysis	NULL
of	NULL
Dpnl/BamHI-digested	NULL
DNA	NULL
samples	NULL
indicated	NULL
that	NULL
these	NULL
Zd	NULL
fusions	NULL
with	NULL
nonacidic	NULL
activation	NULL
domains	NULL
could	NULL
induce	NULL
EBV	NULL
replication	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
.	NULL

Both	NULL
Zd3C	NULL
and	NULL
ZdMeqII339	NULL
were	NULL
able	NULL
to	NULL
drive	NULL
replication	NULL
of	NULL
the	NULL
oriLyt-containing	NULL
plasmid	NULL
(	NULL
pS526	NULL
)	NULL
,	NULL
while	NULL
vector	NULL
alone	NULL
and	NULL
Zd	NULL
were	NULL
inactive	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

ZdVP	NULL
and	NULL
ZdR	NULL
,	NULL
which	NULL
have	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
active	NULL
in	NULL
this	NULL
assay	NULL
(	NULL
5	NULL
)	NULL
,	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
controls	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
Zd	NULL
chimeras	NULL
were	NULL
tested	NULL
in	NULL
CAT	NULL
assays	NULL
against	NULL
the	NULL
DISRUPTION	NULL
OF	NULL
EBV	NULL
LATENCY	NULL
BY	NULL
ZEBRA	NULL
-	NULL
65531	NULL
target	NULL
DPCAT	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
oriLyt	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
5	NULL
)	NULL
.	NULL

All	NULL
the	NULL
Zd	NULL
chimeric	NULL
clones	NULL
activated	NULL
this	NULL
target	NULL
more	NULL
than	NULL
fourfold	NULL
compared	NULL
to	NULL
Zd	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
columns	NULL
4	NULL
through	NULL
7	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
that	NULL
all	NULL
the	NULL
ZEBRA	NULL
domain	NULL
substitution	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
contain	NULL
the	NULL
first	NULL
25	NULL
amino	NULL
acids	NULL
of	NULL
ZEBRA	NULL
.	NULL

As	NULL
has	NULL
been	NULL
previously	NULL
discussed	NULL
,	NULL
this	NULL
region	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
important	NULL
for	NULL
replication	NULL
of	NULL
an	NULL
EBV	NULL
origin-containing	NULL
plasmid	NULL
in	NULL
African	NULL
green	NULL
monkey	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
two	NULL
additional	NULL
clones	NULL
were	NULL
constructed	NULL
,	NULL
Zdx	NULL
and	NULL
ZdxVP	NULL
,	NULL
which	NULL
lack	NULL
this	NULL
25-amino-acid	NULL
region	NULL
.	NULL

Zdx	NULL
contains	NULL
amino	NULL
acids	NULL
131	NULL
to	NULL
227	NULL
of	NULL
ZEBRA	NULL
,	NULL
and	NULL
ZdxVP	NULL
contains	NULL
amino	NULL
acids	NULL
400	NULL
to	NULL
479	NULL
of	NULL
VP16	NULL
fused	NULL
to	NULL
the	NULL
carboxy-terminal	NULL
end	NULL
of	NULL
Zdx	NULL
.	NULL

ZdxVP	NULL
was	NULL
capable	NULL
of	NULL
inducing	NULL
orilyt	NULL
replication	NULL
to	NULL
the	NULL
same	NULL
levels	NULL
as	NULL
ZdVP	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
,	NULL
which	NULL
argues	NULL
that	NULL
the	NULL
N-terminal	NULL
25	NULL
amino	NULL
acids	NULL
do	NULL
not	NULL
contribute	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
ZdVP	NULL
to	NULL
induce	NULL
DNA	NULL
replication	NULL
at	NULL
the	NULL
oriLyt	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

Control	NULL
assays	NULL
containing	NULL
vector	NULL
,	NULL
Zd	NULL
,	NULL
or	NULL
Zdx	NULL
could	NULL
not	NULL
induce	NULL
replication	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
.	NULL

Deletion	NULL
analysis	NULL
of	NULL
the	NULL
Meq	NULL
activation	NULL
region	NULL
.	NULL

As	NULL
discussed	NULL
in	NULL
a	NULL
previous	NULL
section	NULL
,	NULL
sequential	NULL
deletion	NULL
of	NULL
the	NULL
ZEBRA	NULL
activation	NULL
region	NULL
failed	NULL
to	NULL
reveal	NULL
any	NULL
subdomains	NULL
that	NULL
were	NULL
required	NULL
for	NULL
reporter	NULL
gene	NULL
assays	NULL
,	NULL
EA-D	NULL
induction	NULL
,	NULL
or	NULL
orilLyt	NULL
replication	NULL
.	NULL

Sequential	NULL
deletions	NULL
of	NULL
the	NULL
Meq	NULL
activation	NULL
domain	NULL
in	NULL
ZdMeq1II339	NULL
were	NULL
also	NULL
generated	NULL
to	NULL
determine	NULL
if	NULL
this	NULL
pattern	NULL
would	NULL
hold	NULL
true	NULL
for	NULL
a	NULL
fully	NULL
functional	NULL
Zd	NULL
chimera	NULL
.	NULL

Therefore	NULL
,	NULL
deleted	NULL
derivatives	NULL
of	NULL
ZdMeq11339	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
if	NULL
the	NULL
regions	NULL
of	NULL
the	NULL
Meq	NULL
activation	NULL
domain	NULL
which	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
are	NULL
also	NULL
essential	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
viral	NULL
replication	NULL
.	NULL

The	NULL
ZdMeq	NULL
clones	NULL
were	NULL
first	NULL
tested	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
ZEBRA	NULL
targets	NULL
DPCAT	NULL
and	NULL
EABSCAT	NULL
in	NULL
CL16	NULL
and	NULL
Raji	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
with	NULL
progressive	NULL
deletion	NULL
of	NULL
the	NULL
Meq	NULL
domain	NULL
,	NULL
activity	NULL
is	NULL
gradually	NULL
reduced	NULL
on	NULL
the	NULL
DPCAT	NULL
target	NULL
.	NULL

Then	NULL
,	NULL
after	NULL
more	NULL
than	NULL
100	NULL
amino	NULL
acids	NULL
have	NULL
been	NULL
removed	NULL
,	NULL
activation	NULL
capacity	NULL
is	NULL
abolished	NULL
(	NULL
ZdMeqII238	NULL
construct	NULL
)	NULL
.	NULL

On	NULL
the	NULL
EABSCAT	NULL
target	NULL
,	NULL
activity	NULL
is	NULL
substantially	NULL
reduced	NULL
for	NULL
the	NULL
ZdMeqII283	NULL
construct	NULL
but	NULL
is	NULL
completely	NULL
lost	NULL
for	NULL
construct	NULL
ZdMeqII262	NULL
.	NULL

As	NULL
discussed	NULL
below	NULL
,	NULL
this	NULL
overall	NULL
pattern	NULL
is	NULL
reproduced	NULL
in	NULL
the	NULL
bioassays	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

In	NULL
the	NULL
preceding	NULL
sections	NULL
experimentation	NULL
has	NULL
focused	NULL
on	NULL
two	NULL
cell	NULL
lines	NULL
,	NULL
Raji	NULL
and	NULL
CL16	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
EBV	NULL
positive	NULL
and	NULL
both	NULL
of	NULL
which	NULL
contain	NULL
viral	NULL
genomes	NULL
that	NULL
can	NULL
be	NULL
reactivated	NULL
from	NULL
latency	NULL
.	NULL

The	NULL
ZdMeq	NULL
clones	NULL
were	NULL
also	NULL
tested	NULL
by	NULL
CAT	NULL
assay	NULL
in	NULL
two	NULL
additional	NULL
cell	NULL
lines	NULL
:	NULL
the	NULL
BL41/CL16	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
harbors	NULL
latent	NULL
EBV	NULL
which	NULL
can	NULL
not	NULL
be	NULL
induced	NULL
from	NULL
latency	NULL
(	NULL
2	NULL
,	NULL
37	NULL
)	NULL
and	NULL
the	NULL
BJAB	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
is	NULL
EBV	NULL
negative	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
the	NULL
overall	NULL
patterns	NULL
of	NULL
activation	NULL
with	NULL
EABSCAT	NULL
are	NULL
similar	NULL
in	NULL
these	NULL
two	NULL
cell	NULL
lines	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
LC	NULL
(	NULL
1	NULL
)	NULL
_E1	NULL
?	NULL

6	NULL
cells	NULL
012m	NULL
v	NULL
|	NULL
za	NULL
|	NULL
z	NULL
|zavPp|	NULL
zax	NULL
|zaxvP	NULL
assay	NULL
=ulp	NULL
>	NULL
Senet	NULL
==	NULL
>	NULL
1	NULL
|J	NULL
2	NULL
|	NULL
s	NULL
[	NULL
4	NULL
|	NULL
s	NULL
|	NULL
s	NULL
|	NULL
7	NULL
;	NULL
FIG	NULL
.	NULL

7.	NULL
oriLyt	NULL
analysis	NULL
of	NULL
a	NULL
ZEBRA	NULL
chimera	NULL
lacking	NULL
the	NULL
first	NULL
25	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
.	NULL

The	NULL
LOR	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
CL16	NULL
cells	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

The	NULL
upper	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
linearized	NULL
p526	NULL
.	NULL

The	NULL
lower	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
control	NULL
plasmid	NULL
incorporated	NULL
into	NULL
all	NULL
samples	NULL
to	NULL
monitor	NULL
for	NULL
complete	NULL
digestion	NULL
.	NULL

V	NULL
,	NULL
vector	NULL
;	NULL
Z	NULL
,	NULL
ZEBRA	NULL
.	NULL

6552	NULL
_	NULL
ASKOVIC	NULL
AND	NULL
BAUMANN	NULL
A	NULL
ZdMeql1	NULL
CAT	NULL
assay	NULL
v	NULL
|	NULL
za	NULL
|	NULL
z	NULL
|	NULL
238	NULL
|	NULL
262	NULL
|	NULL
283	NULL
|	NULL
sos	NULL
|	NULL
339	NULL
CL16	NULL
tog	NULL
|oa	NULL
|	NULL
1	NULL
[	NULL
41	NULL
]	NULL
os	NULL
|	NULL
3s	NULL
|	NULL
63	NULL
|	NULL
122	NULL
]	NULL
12s	NULL
hof	NULL
magee	NULL
,	NULL
|	NULL
os	NULL
|	NULL
1	NULL
|	NULL
65	NULL
|	NULL
110	NULL
|	NULL
14	NULL
|	NULL
52	NULL
|14.6|	NULL
22.8	NULL
[	NULL
~Btavclis	NULL
Erssaat	NULL
[	NULL
wo	NULL
|	NULL
1	NULL
f10.6	NULL
|	NULL
0.7	NULL
|	NULL
1.1	NULL
|	NULL
1.0	NULL
[	NULL
14.6	NULL
]	NULL
10.2	NULL
N/D	NULL
|	NULL
1.2	NULL
|	NULL
2.0	NULL
|	NULL
4.6	NULL
|	NULL
13.3	NULL
|	NULL
9.5	NULL
BJAG	NULL
easscatr	NULL
|	NULL
1.5	NULL
|	NULL
1	NULL
B	NULL
ZdMeqll	NULL
Raji	NULL
cells	NULL
V	NULL
|	NULL
24	NULL
|	NULL
238	NULL
|	NULL
262	NULL
|	NULL
283	NULL
|	NULL
308	NULL
|	NULL
339	NULL
a	NULL
EA-D	NULL
1	NULL
[	NULL
2	NULL
|	NULL
3	NULL
|	NULL
4	NULL
|	NULL
5	NULL
|	NULL
6	NULL
|	NULL
7	NULL
C	NULL
ZdMeqll	NULL
CL16	NULL
cells	NULL
LOR	NULL
assay	NULL
V	NULL
|	NULL
Z4	NULL
|	NULL
Z	NULL
|	NULL
238	NULL
|	NULL
262	NULL
|	NULL
283	NULL
|	NULL
308	NULL
|	NULL
339	NULL
mal	NULL
..	NULL
==p	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
ZEBRA	NULL
chimera	NULL
ZdMe-q1I339	NULL
,	NULL
designated	NULL
by	NULL
the	NULL
last	NULL
amino	NULL
acid	NULL
retained	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CAT	NULL
assay	NULL
analysis	NULL
of	NULL
the	NULL
ZdMeqII	NULL
subclones	NULL
.	NULL

The	NULL
target	NULL
DPCAT	NULL
was	NULL
employed	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

EABSCAT	NULL
was	NULL
used	NULL
as	NULL
a	NULL
target	NULL
in	NULL
Raji	NULL
,	NULL
BL41/CL16	NULL
,	NULL
and	NULL
BJAB	NULL
cells	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
as	NULL
fold	NULL
activation	NULL
relative	NULL
to	NULL
Zd	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
arbitrarily	NULL
set	NULL
to	NULL
a	NULL
value	NULL
of	NULL
one	NULL
.	NULL

Each	NULL
value	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

V	NULL
,	NULL
vector	NULL
;	NULL
Z	NULL
,	NULL
ZEBRA	NULL
;	NULL
N/D	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Induction	NULL
of	NULL
EA-D	NULL
in	NULL
Raji	NULL
cells	NULL
by	NULL
ZdMeq11339	NULL
deletion	NULL
mutants	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
were	NULL
prepared	NULL
3	NULL
days	NULL
post-transfection	NULL
.	NULL

Equivalents	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
loaded	NULL
into	NULL
each	NULL
lane	NULL
and	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
primary	NULL
antibody	NULL
was	NULL
mouse	NULL
anti-EA-D	NULL
(	NULL
Advanced	NULL
Biotechnologies	NULL
)	NULL
,	NULL
and	NULL
the	NULL
secondary	NULL
antibody	NULL
was	NULL
goat	NULL
antimouse	NULL
antibody	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
by	NULL
using	NULL
an	NULL
ECL	NULL
kit	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
specifications	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Induction	NULL
of	NULL
replication	NULL
of	NULL
the	NULL
p526	NULL
plasmid	NULL
by	NULL
the	NULL
ZdMeqII	NULL
clones	NULL
in	NULL
CL16	NULL
cells	NULL
.	NULL

DNA	NULL
from	NULL
0.8	NULL
x	NULL
10°	NULL
cells	NULL
was	NULL
digested	NULL
with	NULL
DpnI	NULL
and	NULL
BemHI	NULL
and	NULL
subjected	NULL
to	NULL
Southern	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

The	NULL
upper	NULL
and	NULL
the	NULL
lower	NULL
arrows	NULL
represent	NULL
the	NULL
positions	NULL
of	NULL
p526	NULL
and	NULL
of	NULL
the	NULL
digestion	NULL
control	NULL
plasmid	NULL
,	NULL
respectively	NULL
.	NULL

that	NULL
the	NULL
results	NULL
are	NULL
not	NULL
dependent	NULL
on	NULL
the	NULL
individual	NULL
cell	NULL
line	NULL
used	NULL
or	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
latent	NULL
EBV	NULL
.	NULL

The	NULL
ZdMeq	NULL
constructs	NULL
were	NULL
next	NULL
tested	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
EA-D	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

The	NULL
results	NULL
from	NULL
the	NULL
EA-D	NULL
induction	NULL
assay	NULL
are	NULL
in	NULL
general	NULL
agreement	NULL
with	NULL
those	NULL
seen	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
EA-D	NULL
promoter	NULL
in	NULL
CAT	NULL
assays	NULL
,	NULL
although	NULL
the	NULL
loss	NULL
of	NULL
activity	NULL
in	NULL
the	NULL
EA-D	NULL
assay	NULL
seems	NULL
to	NULL
be	NULL
more	NULL
precipitous	NULL
after	NULL
deletion	NULL
beyond	NULL
amino	NULL
acid	NULL
283	NULL
of	NULL
Meq	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
experiments	NULL
suggest	NULL
that	NULL
amino	NULL
acids	NULL
309	NULL
to	NULL
339	NULL
of	NULL
Meq	NULL
are	NULL
dispensable	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
EA-D	NULL
from	NULL
the	NULL
latent	NULL
viral	NULL
genome	NULL
.	NULL

These	NULL
results	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
ZdMeq	NULL
clones	NULL
,	NULL
since	NULL
immunoblot	NULL
analysis	NULL
with	NULL
polyclonal	NULL
antisera	NULL
directed	NULL
against	NULL
ZEBRA	NULL
demonstrated	NULL
that	NULL
all	NULL
constructs	NULL
are	NULL
expressed	NULL
in	NULL
abundance	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
ZdMeq	NULL
chimeras	NULL
were	NULL
tested	NULL
in	NULL
the	NULL
LOR	NULL
assay	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
this	NULL
assay	NULL
clone	NULL
ZdMeqII262	NULL
,	NULL
which	NULL
was	NULL
clearly	NULL
inactive	NULL
at	NULL
EA-D	NULL
induction	NULL
and	NULL
in	NULL
CAT	NULL
assays	NULL
against	NULL
the	NULL
EABSCAT	NULL
target	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
EBV	NULL
J.	NULL
ViRoL	NULL
.	NULL

orilLyt	NULL
replication	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

In	NULL
support	NULL
of	NULL
these	NULL
results	NULL
,	NULL
Zd-MeqII262	NULL
was	NULL
also	NULL
active	NULL
when	NULL
tested	NULL
against	NULL
the	NULL
DPCAT	NULL
(	NULL
orilyt	NULL
)	NULL
target	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

As	NULL
discussed	NULL
above	NULL
for	NULL
the	NULL
N-terminal	NULL
ZEBRA	NULL
mutants	NULL
,	NULL
we	NULL
believe	NULL
that	NULL
these	NULL
differences	NULL
are	NULL
attributable	NULL
to	NULL
a	NULL
higher	NULL
sensitivity	NULL
of	NULL
the	NULL
oriLyt	NULL
assay	NULL
and	NULL
to	NULL
a	NULL
greater	NULL
responsiveness	NULL
of	NULL
the	NULL
DPCAT	NULL
target	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
various	NULL
targets	NULL
of	NULL
ZEBRA	NULL
seem	NULL
to	NULL
show	NULL
individually	NULL
consistent	NULL
specificities	NULL
and	NULL
sensitivities	NULL
that	NULL
are	NULL
independent	NULL
of	NULL
the	NULL
type	NULL
of	NULL
assay	NULL
employed	NULL
(	NULL
reporter	NULL
gene	NULL
assay	NULL
or	NULL
bioassay	NULL
)	NULL
.	NULL

In	NULL
gen-eral	NULL
,	NULL
the	NULL
results	NULL
seen	NULL
with	NULL
reporter	NULL
gene	NULL
assays	NULL
accurately	NULL
reflected	NULL
gene	NULL
activation	NULL
from	NULL
the	NULL
context	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
as	NULL
tested	NULL
by	NULL
the	NULL
bioassays	NULL
employed	NULL
here	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Lastly	NULL
,	NULL
the	NULL
results	NULL
of	NULL
deletion	NULL
analysis	NULL
with	NULL
the	NULL
ZdMeq	NULL
chimera	NULL
were	NULL
consistent	NULL
with	NULL
the	NULL
pattern	NULL
seen	NULL
for	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
wild-type	NULL
ZEBRA	NULL
domain	NULL
.	NULL

Specifically	NULL
,	NULL
the	NULL
capacity	NULL
to	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
could	NULL
not	NULL
be	NULL
separated	NULL
from	NULL
,	NULL
and	NULL
was	NULL
a	NULL
prerequisite	NULL
for	NULL
,	NULL
the	NULL
ability	NULL
to	NULL
disrupt	NULL
virus	NULL
latency	NULL
and	NULL
to	NULL
stimulate	NULL
replication	NULL
at	NULL
the	NULL
EBV	NULL
oriLyt	NULL
.	NULL

DISCUSSION	NULL
Activation	NULL
domains	NULL
share	NULL
very	NULL
little	NULL
direct	NULL
amino	NULL
acid	NULL
sequence	NULL
homology	NULL
and	NULL
are	NULL
often	NULL
grouped	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
BIO	NULL
ASSAYS	NULL
LOR	NULL
CAT	NULL
ASSAYS	NULL
DPCAT	NULL
EAD	NULL
EABS	NULL
CAT	NULL
CL16	NULL
Raji	NULL
CL16	NULL
Raji	NULL
VECTOR	NULL
ZEBRA	NULL
+	NULL
+	NULL
+	NULL
ZA	NULL
27/53	NULL
+	NULL
+	NULL
+	NULL
ZA	NULL
52778	NULL
ZA	NULL
77/03	NULL
ZA	NULL
102/128	NULL
ZA	NULL
127/153	NULL
T	NULL
2-245	NULL
%	NULL
25-245	NULL
%	NULL
51-245	NULL
277-245	NULL
%	NULL
99-245	NULL
Z	NULL
131-245	NULL
Zd	NULL
ZIR	NULL
ZdMeqIl	NULL
339	NULL
ZdMeqIl	NULL
308	NULL
ZdMeqIl	NULL
283	NULL
ZdMeqI	NULL
262	NULL
+	NULL
+	NULL
ZdMeqI	NULL
238	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Schematic	NULL
diagram	NULL
summarizing	NULL
the	NULL
results	NULL
of	NULL
assays	NULL
performed	NULL
with	NULL
CL16	NULL
and	NULL
Raji	NULL
cells	NULL
.	NULL

The	NULL
various	NULL
constructs	NULL
employed	NULL
are	NULL
given	NULL
in	NULL
the	NULL
left	NULL
column	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
amino	NULL
acid	NULL
content	NULL
,	NULL
into	NULL
acidic	NULL
,	NULL
proline-rich	NULL
,	NULL
and	NULL
glutamine-rich	NULL
classes	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
domain	NULL
of	NULL
ZEBRA	NULL
can	NULL
not	NULL
be	NULL
classified	NULL
into	NULL
any	NULL
of	NULL
these	NULL
groups	NULL
.	NULL

Not	NULL
surprisingly	NULL
,	NULL
an	NULL
amino	NULL
acid	NULL
homology	NULL
search	NULL
of	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
ZEBRA	NULL
revealed	NULL
no	NULL
significant	NULL
homology	NULL
to	NULL
any	NULL
protein	NULL
in	NULL
the	NULL
Gen-Bank	NULL
database	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Studies	NULL
on	NULL
basal	NULL
transcription	NULL
have	NULL
suggested	NULL
that	NULL
acidic	NULL
and	NULL
glutamine-rich	NULL
activation	NULL
regions	NULL
bind	NULL
to	NULL
specific	NULL
TBP	NULL
-associated	NULL
factors	NULL
within	NULL
the	NULL
TFIID	NULL
complex	NULL
and	NULL
thus	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
(	NULL
25	NULL
)	NULL
.	NULL

ZEBRA	NULL
itself	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
TBP	NULL
and	NULL
TFIIA	NULL
through	NULL
interaction	NULL
with	NULL
protein	NULL
sequences	NULL
within	NULL
its	NULL
first	NULL
exon	NULL
that	NULL
overlap	NULL
its	NULL
activation	NULL
domain	NULL
(	NULL
31	NULL
)	NULL
.	NULL

This	NULL
report	NULL
,	NULL
together	NULL
with	NULL
previously	NULL
published	NULL
papers	NULL
(	NULL
3	NULL
,	NULL
5	NULL
)	NULL
,	NULL
clearly	NULL
demonstrates	NULL
that	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
ZEBRA	NULL
can	NULL
be	NULL
replaced	NULL
by	NULL
heterologous	NULL
nonacidic	NULL
activation	NULL
domains	NULL
,	NULL
so	NULL
that	NULL
the	NULL
resulting	NULL
ZEBRA	NULL
chimeric	NULL
proteins	NULL
have	NULL
been	NULL
restored	NULL
to	NULL
wild-type	NULL
activity	NULL
.	NULL

Both	NULL
the	NULL
glutamine-rich	NULL
domain	NULL
of	NULL
the	NULL
EBNA	NULL
3C	NULL
protein	NULL
and	NULL
the	NULL
proline-rich	NULL
domain	NULL
of	NULL
the	NULL
Meq	NULL
protein	NULL
were	NULL
capable	NULL
of	NULL
substituting	NULL
for	NULL
the	NULL
wild-type	NULL
ZEBRA	NULL
activation	NULL
region	NULL
.	NULL

The	NULL
ZEBRA	NULL
chimeras	NULL
were	NULL
capable	NULL
of	NULL
disrupting	NULL
EBV	NULL
latency	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
virus	NULL
early	NULL
antigen	NULL
and	NULL
to	NULL
stimulate	NULL
replication	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
an	NULL
EBV	NULL
lytic	NULL
origin	NULL
.	NULL

These	NULL
experiments	NULL
also	NULL
address	NULL
the	NULL
broad	NULL
biological	NULL
question	NULL
of	NULL
whether	NULL
activation	NULL
regions	NULL
confer	NULL
specificity	NULL
or	NULL
participate	NULL
in	NULL
the	NULL
uniqueness	NULL
of	NULL
a	NULL
protein	NULL
's	NULL
function	NULL
.	NULL

In	NULL
the	NULL
system	NULL
employed	NULL
here	NULL
,	NULL
activation	NULL
domains	NULL
are	NULL
readily	NULL
exchangeable	NULL
and	NULL
do	NULL
not	NULL
confer	NULL
obvious	NULL
functional	NULL
specificity	NULL
.	NULL

The	NULL
results	NULL
described	NULL
here	NULL
contrast	NULL
with	NULL
the	NULL
study	NULL
of	NULL
Schep-ers	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40a	NULL
)	NULL
in	NULL
which	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
was	NULL
found	NULL
to	NULL
be	NULL
required	NULL
for	NULL
replication	NULL
of	NULL
a	NULL
modified	NULL
EBV	NULL
oriLyt	NULL
region	NULL
.	NULL

In	NULL
that	NULL
study	NULL
all	NULL
ZEBRA	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
oriLyt	NULL
region	NULL
were	NULL
mutated	NULL
to	NULL
GALA	NULL
binding	NULL
sites	NULL
;	NULL
and	NULL
GALA	NULL
chimeras	NULL
containing	NULL
heterologous	NULL
activation	NULL
domains	NULL
(	NULL
other	NULL
than	NULL
ZEBRA	NULL
's	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
incapable	NULL
of	NULL
driving	NULL
oriLyt	NULL
plasmid	NULL
replication	NULL
in	NULL
D98/HR1	NULL
cells	NULL
.	NULL

The	NULL
different	NULL
result	NULL
obtained	NULL
in	NULL
our	NULL
study	NULL
may	NULL
reflect	NULL
fundamental	NULL
differences	NULL
in	NULL
the	NULL
GAL4	NULL
and	NULL
ZEBRA	NULL
proteins	NULL
.	NULL

Alternately	NULL
,	NULL
the	NULL
introduction	NULL
of	NULL
mutations	NULL
into	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
may	NULL
have	NULL
altered	NULL
its	NULL
response	NULL
to	NULL
direct	NULL
stimulation	NULL
.	NULL

Lastly	NULL
,	NULL
these	NULL
variant	NULL
experimental	NULL
outcomes	NULL
may	NULL
reflect	NULL
cell	NULL
type-specific	NULL
differences	NULL
in	NULL
the	NULL
requirements	NULL
for	NULL
EBV	NULL
lytic	NULL
replication	NULL
.	NULL

The	NULL
ease	NULL
with	NULL
which	NULL
ZEBRA	NULL
's	NULL
activation	NULL
region	NULL
can	NULL
be	NULL
exchanged	NULL
in	NULL
the	NULL
B-lymphocyte	NULL
system	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
unique	NULL
properties	NULL
of	NULL
the	NULL
ZEBRA	NULL
bZIP	NULL
-like	NULL
region	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
mediating	NULL
dimerization	NULL
and	NULL
DNA	NULL
recognition	NULL
,	NULL
the	NULL
bZIP	NULL
-like	NULL
region	NULL
in	NULL
ZEBRA	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
cellular	NULL
proteins	NULL
p53	NULL
and	NULL
NF-	NULL
«	NULL
B/p65	NULL
and	NULL
to	NULL
the	NULL
viral	NULL
BMRF1	NULL
(	NULL
EA-D	NULL
)	NULL
protein	NULL
(	NULL
21	NULL
,	NULL
46	NULL
,	NULL
47	NULL
)	NULL
.	NULL

The	NULL
bZIP	NULL
region	NULL
has	NULL
also	NULL
been	NULL
recently	NULL
demonstrated	NULL
to	NULL
mediate	NULL
growth	NULL
arrest	NULL
at	NULL
the	NULL
GO/G1	NULL
phase	NULL
in	NULL
epithelial	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Perhaps	NULL
ZEBRA	NULL
's	NULL
specificity	NULL
for	NULL
altering	NULL
cellular	NULL
and	NULL
viral	NULL
gene	NULL
expression	NULL
pathways	NULL
resides	NULL
in	NULL
its	NULL
multifunctional	NULL
bZIP-like	NULL
carboxyl-terminal	NULL
region	NULL
.	NULL

Our	NULL
analysis	NULL
of	NULL
small	NULL
internal	NULL
deletions	NULL
within	NULL
exon	NULL
1	NULL
of	NULL
ZEBRA	NULL
indicated	NULL
that	NULL
the	NULL
activities	NULL
associated	NULL
with	NULL
this	NULL
exon	NULL
are	NULL
not	NULL
contributed	NULL
by	NULL
specific	NULL
subdomains	NULL
but	NULL
are	NULL
spread	NULL
throughout	NULL
exon	NULL
1	NULL
and	NULL
therefore	NULL
can	NULL
not	NULL
be	NULL
inactivated	NULL
by	NULL
deleting	NULL
localized	NULL
regions	NULL
.	NULL

Studies	NULL
with	NULL
Vero	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
and	NULL
D98/HR1	NULL
cells	NULL
(	NULL
41	NULL
)	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
is	NULL
unique	NULL
and	NULL
contains	NULL
essential	NULL
sequences	NULL
which	NULL
can	NULL
not	NULL
be	NULL
substituted	NULL
for	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
these	NULL
studies	NULL
,	NULL
conducted	NULL
with	NULL
EBV-positive	NULL
human	NULL
lymphocyte	NULL
lines	NULL
,	NULL
suggest	NULL
that	NULL
both	NULL
acidic	NULL
and	NULL
nonacidic	NULL
heterologous	NULL
activation	NULL
regions	NULL
can	NULL
fully	NULL
substitute	NULL
for	NULL
ZEBRA	NULL
's	NULL
activation	NULL
domain	NULL
.	NULL

Furthermore	NULL
,	NULL
de	NULL
DISRUPTION	NULL
OF	NULL
EBV	NULL
LATENCY	NULL
BY	NULL
ZEBRA	NULL
-	NULL
65533	NULL
letion	NULL
of	NULL
the	NULL
N-terminal	NULL
25	NULL
amino	NULL
acids	NULL
of	NULL
ZEBRA	NULL
did	NULL
not	NULL
obviously	NULL
impair	NULL
its	NULL
ability	NULL
to	NULL
support	NULL
DNA	NULL
replication	NULL
at	NULL
the	NULL
EBV	NULL
lytic	NULL
origin	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
our	NULL
conclusions	NULL
are	NULL
independent	NULL
of	NULL
the	NULL
particular	NULL
B-cell	NULL
line	NULL
employed	NULL
,	NULL
as	NULL
the	NULL
four	NULL
distinct	NULL
cell	NULL
lines	NULL
employed	NULL
here	NULL
yielded	NULL
similar	NULL
results	NULL
.	NULL

These	NULL
cell	NULL
lines	NULL
included	NULL
EBV-negative	NULL
and	NULL
-positive	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
tightly	NULL
latent	NULL
lymphocyte	NULL
line	NULL
(	NULL
BL41/CL16	NULL
)	NULL
.	NULL

Three	NULL
distinct	NULL
assays	NULL
were	NULL
used	NULL
to	NULL
test	NULL
each	NULL
of	NULL
the	NULL
various	NULL
clones	NULL
employed	NULL
in	NULL
these	NULL
studies	NULL
:	NULL
reporter	NULL
gene	NULL
assays	NULL
,	NULL
EA-D	NULL
induction	NULL
,	NULL
and	NULL
a	NULL
stringent	NULL
oriLyt	NULL
replication	NULL
assay	NULL
.	NULL

Although	NULL
minor	NULL
differences	NULL
were	NULL
noted	NULL
for	NULL
some	NULL
of	NULL
the	NULL
sets	NULL
of	NULL
clones	NULL
,	NULL
we	NULL
attribute	NULL
these	NULL
to	NULL
the	NULL
observation	NULL
that	NULL
the	NULL
CAT	NULL
assays	NULL
and	NULL
the	NULL
origin	NULL
assays	NULL
appeared	NULL
slightly	NULL
more	NULL
sensitive	NULL
than	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
EA-D	NULL
induction	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
two	NULL
targets	NULL
employed	NULL
in	NULL
the	NULL
CAT	NULL
assays	NULL
represent	NULL
unique	NULL
native	NULL
EBV	NULL
promoters	NULL
that	NULL
differ	NULL
in	NULL
their	NULL
responsiveness	NULL
to	NULL
ZEBRA	NULL
transactivation	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
,	NULL
an	NULL
observation	NULL
which	NULL
may	NULL
explain	NULL
some	NULL
of	NULL
the	NULL
minor	NULL
differences	NULL
observed	NULL
in	NULL
our	NULL
studies	NULL
.	NULL

However	NULL
,	NULL
as	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
overall	NULL
the	NULL
results	NULL
are	NULL
in	NULL
excellent	NULL
agreement	NULL
among	NULL
the	NULL
various	NULL
assays	NULL
performed	NULL
.	NULL

Our	NULL
results	NULL
may	NULL
differ	NULL
from	NULL
those	NULL
of	NULL
other	NULL
investigators	NULL
because	NULL
of	NULL
the	NULL
inherent	NULL
differences	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
utilized	NULL
.	NULL

Human	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
the	NULL
natural	NULL
host	NULL
cells	NULL
for	NULL
latent	NULL
EBV	NULL
,	NULL
may	NULL
provide	NULL
a	NULL
unique	NULL
environment	NULL
for	NULL
the	NULL
disruption	NULL
of	NULL
EBV	NULL
latency	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
lytic	NULL
replication	NULL
which	NULL
is	NULL
not	NULL
duplicated	NULL
by	NULL
other	NULL
cell	NULL
lines	NULL
.	NULL

One	NULL
obvious	NULL
possible	NULL
complication	NULL
of	NULL
this	NULL
system	NULL
,	NULL
which	NULL
utilizes	NULL
EBV-infected	NULL
cells	NULL
,	NULL
is	NULL
the	NULL
potential	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
endogenous	NULL
ZEBRA	NULL
expression	NULL
by	NULL
ZEBRA	NULL
derivatives	NULL
.	NULL

We	NULL
feel	NULL
that	NULL
it	NULL
is	NULL
highly	NULL
unlikely	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
endogenous	NULL
ZEBRA	NULL
expression	NULL
can	NULL
account	NULL
for	NULL
our	NULL
results	NULL
for	NULL
two	NULL
reasons	NULL
:	NULL
(	NULL
i	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
fails	NULL
to	NULL
detect	NULL
any	NULL
induction	NULL
of	NULL
endogenous	NULL
ZEBRA	NULL
expression	NULL
in	NULL
the	NULL
assays	NULL
performed	NULL
here	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
previously	NULL
published	NULL
studies	NULL
from	NULL
several	NULL
different	NULL
laboratories	NULL
have	NULL
demonstrated	NULL
that	NULL
ex-ogenously	NULL
introduced	NULL
ZEBRA	NULL
can	NULL
not	NULL
induce	NULL
endogenous	NULL
ZEBRA	NULL
expression	NULL
in	NULL
human	NULL
B-cell	NULL
lines	NULL
(	NULL
27	NULL
,	NULL
28	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
it	NULL
must	NULL
be	NULL
stated	NULL
that	NULL
lytic	NULL
replication	NULL
of	NULL
the	NULL
endogenous	NULL
viral	NULL
genome	NULL
was	NULL
not	NULL
directly	NULL
tested	NULL
for	NULL
in	NULL
the	NULL
studies	NULL
described	NULL
herein	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
reiterated	NULL
that	NULL
the	NULL
oriLyt	NULL
plasmid	NULL
assay	NULL
employed	NULL
here	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
seven	NULL
lytic-cycle	NULL
viral-gene	NULL
products	NULL
that	NULL
must	NULL
be	NULL
provided	NULL
in	NULL
trans	NULL
by	NULL
the	NULL
endogenous	NULL
genome	NULL
,	NULL
an	NULL
event	NULL
unlikely	NULL
to	NULL
occur	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
true	NULL
lytic	NULL
replication	NULL
in	NULL
EBV-positive	NULL
cells	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
studies	NULL
indicate	NULL
that	NULL
ZEBRA	NULL
's	NULL
capacity	NULL
to	NULL
activate	NULL
transcription	NULL
can	NULL
not	NULL
be	NULL
readily	NULL
separated	NULL
from	NULL
its	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
lytic	NULL
replication	NULL
and	NULL
that	NULL
ZEBRA	NULL
's	NULL
function	NULL
as	NULL
a	NULL
transactivator	NULL
may	NULL
be	NULL
intimately	NULL
involved	NULL
in	NULL
all	NULL
its	NULL
activities	NULL
.	NULL

Overall	NULL
,	NULL
the	NULL
results	NULL
from	NULL
reporter	NULL
gene	NULL
assays	NULL
,	NULL
early	NULL
antigen	NULL
induction	NULL
,	NULL
and	NULL
the	NULL
LOR	NULL
assays	NULL
were	NULL
in	NULL
strong	NULL
agreement	NULL
with	NULL
each	NULL
other	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
ZEBRA	NULL
to	NULL
function	NULL
when	NULL
fused	NULL
to	NULL
many	NULL
different	NULL
types	NULL
of	NULL
activation	NULL
regions	NULL
suggests	NULL
that	NULL
ZEBRA	NULL
may	NULL
be	NULL
useful	NULL
for	NULL
mapping	NULL
putative	NULL
activation	NULL
regions	NULL
(	NULL
3	NULL
)	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Erik	NULL
Flemington	NULL
,	NULL
Clare	NULL
Sample	NULL
,	NULL
and	NULL
Michael	NULL
Carey	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
plasmids	NULL
,	NULL
Eva	NULL
Bengtén	NULL
for	NULL
help	NULL
in	NULL
manuscript	NULL
preparation	NULL
,	NULL
and	NULL
Greg	NULL
Chinchar	NULL
,	NULL
Chris	NULL
Meade	NULL
,	NULL
and	NULL
Amy	NULL
Baumann	NULL
for	NULL
proofreading	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Altschul	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
W.	NULL
Gish	NULL
,	NULL
W.	NULL
Miller	NULL
,	NULL
E.	NULL
Myers	NULL
,	NULL
and	NULL
D.	NULL
Lipman	NULL
.	NULL

1990	NULL
.	NULL

Basic	NULL
local	NULL
alignment	NULL
search	NULL
tool	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

215:403-410.	NULL
.	NULL

Askovic	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Baumann	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

.	NULL

Askovic	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Baumann	NULL
.	NULL

1997	NULL
.	NULL

An	NULL
alternative	NULL
system	NULL
for	NULL
detecting	NULL
and	NULL
mapping	NULL
activation	NULL
domains	NULL
.	NULL

BioTechniques	NULL
22:948-951	NULL
.	NULL

4	NULL
.	NULL

Baumann	NULL
,	NULL
R.	NULL
,	NULL
E.	NULL
Grogan	NULL
,	NULL
M.	NULL
Ptashne	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1993	NULL
.	NULL

Changing	NULL
Ep-	NULL
to	NULL
bo	NULL
6554	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

ASKOVIC	NULL
AND	NULL
BAUMANN	NULL
stein-Barr	NULL
viral	NULL
ZEBRA	NULL
protein	NULL
into	NULL
a	NULL
more	NULL
powerful	NULL
activator	NULL
enhances	NULL
its	NULL
capacity	NULL
to	NULL
disrupt	NULL
latency	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:4436-4440.	NULL
.	NULL

Baumann	NULL
,	NULL
R.	NULL
,	NULL
G.	NULL
Warren	NULL
,	NULL
and	NULL
S.	NULL
Askovic	NULL
.	NULL

1995	NULL
.	NULL

Restoration	NULL
of	NULL
the	NULL
Epstein	NULL
Barr	NULL
virus	NULL
ZEBRA	NULL
protein	NULL
's	NULL
capacity	NULL
to	NULL
disrupt	NULL
latency	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
heterologous	NULL
activation	NULL
regions	NULL
.	NULL

Virology	NULL
211:64-72.	NULL
.	NULL

Cayrol	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
E.	NULL
K.	NULL
Flemington	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
bZIP	NULL
tran	NULL
scription	NULL
factor	NULL
Zta	NULL
causes	NULL
GO/G1	NULL
cell	NULL
cycle	NULL
arrest	NULL
through	NULL
induction	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitors	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:2748-2759.	NULL
.	NULL

Cayrol	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
E.	NULL
K.	NULL
Flemington	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
of	NULL
cellular	NULL
target	NULL
genes	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
Zita	NULL
:	NULL
activation	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
Bigh3	NULL
(	NULL
TGF-Bigh3	NULL
)	NULL
and	NULL
TGF-B1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4206-4212.	NULL
.	NULL

Cayrol	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
E.	NULL
K.	NULL
Flemington	NULL
.	NULL

1996	NULL
.	NULL

G0/G1	NULL
growth	NULL
arrest	NULL
mediated	NULL
by	NULL
a	NULL
region	NULL
encompassing	NULL
the	NULL
basic	NULL
leucine	NULL
zipper	NULL
(	NULL
bZIP	NULL
)	NULL
domain	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
Zta	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:31799-31802.	NULL
.	NULL

Chavrier	NULL
,	NULL
P.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
A.	NULL
Chevallier-Greco	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
promoter	NULL
DR	NULL
contains	NULL
a	NULL
cis-acting	NULL
clement	NULL
responsive	NULL
to	NULL
the	NULL
EBV	NULL
transactivator	NULL
EB1	NULL
and	NULL
an	NULL
enhancer	NULL
with	NULL
constitutive	NULL
and	NULL
inducible	NULL
activities	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:607-614	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-encoded	NULL
trans-acting	NULL
fac-tors	NULL
,	NULL
EB1	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
early	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
DR	NULL
enhancer	NULL
contains	NULL
two	NULL
functionally	NULL
different	NULL
domains	NULL
:	NULL
domain	NULL
A	NULL
is	NULL
constitutive	NULL
and	NULL
cell	NULL
specific	NULL
,	NULL
domain	NULL
B	NULL
is	NULL
transactivated	NULL
by	NULL
the	NULL
EBV	NULL
carly	NULL
protein	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:615-623	NULL
.	NULL

Chi	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
M.	NULL
Carey	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
ZEBRA	NULL
activation	NULL
domain	NULL
:	NULL
modular	NULL
organization	NULL
and	NULL
mechanism	NULL
of	NULL
action	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:7045-7055	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1985	NULL
.	NULL

Activation	NULL
of	NULL
expression	NULL
of	NULL
latent	NULL
Epstein-Barr	NULL
herpesvirus	NULL
after	NULL
gene	NULL
transfer	NULL
with	NULL
a	NULL
small	NULL
cloned	NULL
subfragment	NULL
of	NULL
heterogenous	NULL
viral	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:4085-4089	NULL
.	NULL

Cox	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:313-321	NULL
.	NULL

Davis	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
and	NULL
E.	NULL
Huang	NULL
.	NULL

1988	NULL
.	NULL

Transfer	NULL
and	NULL
expression	NULL
of	NULL
plasmids	NULL
containing	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
gene	NULL
1	NULL
promoter	NULL
enhancer	NULL
sequences	NULL
in	NULL
eukaryotic	NULL
and	NULL
prokaryotic	NULL
cells	NULL
.	NULL

Biotechnol	NULL
.	NULL

Appl	NULL
.	NULL

Biochem	NULL
.	NULL

10:6-12	NULL
.	NULL

Fixman	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1992.	NULL
frans-acting	NULL
requre-ments	NULL
for	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
ori-Lyt	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5030-5039	NULL
.	NULL

Fixman	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1995	NULL
.	NULL

Replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
oriLyt	NULL
:	NULL
lack	NULL
of	NULL
a	NULL
dedicated	NULL
virally	NULL
encoded	NULL
origin-binding	NULL
protein	NULL
and	NULL
dependence	NULL
on	NULL
Zta	NULL
in	NULL
cotransfection	NULL
assays	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:2998-3006	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
M.	NULL
Borras	NULL
,	NULL
J.	NULL
P.	NULL
Lytle	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
protein	NULL
transactivation	NULL
domain	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:922-929	NULL
.	NULL

Giot	NULL
,	NULL
J.	NULL
,	NULL
I.	NULL
Mikaelian	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
E.	NULL
Mante	NULL
,	NULL
I.	NULL
Joab	NULL
,	NULL
J.	NULL
Nicholas	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
interference	NULL
between	NULL
the	NULL
EBV	NULL
transcription	NULL
factors	NULL
EB1	NULL
and	NULL
R	NULL
:	NULL
both	NULL
DNA-binding	NULL
and	NULL
activation	NULL
domains	NULL
of	NULL
EB1	NULL
are	NULL
required	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1251-1258	NULL
.	NULL

Gruffat	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
Moreno	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
ORL	NULL
,	NULL
,	NULL
enhancer	NULL
is	NULL
not	NULL
B-cell	NULL
specific	NULL
and	NULL
does	NULL
not	NULL
respond	NULL
synergistically	NULL
to	NULL
the	NULL
EBV	NULL
transcription	NULL
factors	NULL
R	NULL
and	NULL
Z.	NULL
J.	NULL
Virol	NULL
.	NULL

64:2810-2818	NULL
.	NULL

Gutsch	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
E.	NULL
A.	NULL
Holley-Guthrie	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Blanar	NULL
,	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Kenney	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
bZIP	NULL
transactivator	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
,	NULL
BZLF1	NULL
,	NULL
functionally	NULL
and	NULL
physically	NULL
interacts	NULL
with	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1939-1948	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
oriLyt	NULL
,	NULL
a	NULL
lytic	NULL
origin	NULL
of	NULL
DNA	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Cell	NULL
55:1427-433	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
,	NULL
R	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
cytoplasmic	NULL
early	NULL
anti-gen.	NULL
J.	NULL
Virol	NULL
.	NULL

62:2274-2284	NULL
.	NULL

Hatfull	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
T.	NULL
Bankier	NULL
,	NULL
B.	NULL
G.	NULL
Barrell	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farell	NULL
.	NULL

1988	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
RAJI	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
.	NULL

Virology	NULL
164:334-340.	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
O.	NULL
J.	NULL
Weinzieri	NULL
,	NULL
G.	NULL
Gill	NULL
,	NULL
J.	NULL
L.	NULL
Chen	NULL
,	NULL
B.	NULL
D.	NULL
Dynlacht	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1993	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
Drosophila	NULL
TAF110	NULL
reveal	NULL
properties	NULL
expected	NULL
of	NULL
coactivators	NULL
.	NULL

Cell	NULL
72:247-260	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
G.	NULL
E.	NULL
Holley	NULL
,	NULL
J.	NULL
C.	NULL
Lin	NULL
,	NULL
E.	NULL
C.	NULL
Mar	NULL
,	NULL
and	NULL
J.	NULL
Pagano	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
BZLF1	NULL
immediate-early	NULL
gene	NULL
product	NULL
differentially	NULL
affects	NULL
latent	NULL
versus	NULL
productive	NULL
EBV	NULL
promoters	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63	NULL
:	NULL
1729-1736	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

Kolman	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
N.	NULL
Taylor	NULL
,	NULL
L.	NULL
Gradoville	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1996	NULL
.	NULL

Comparing	NULL
transcriptional	NULL
activation	NULL
and	NULL
autostimulation	NULL
by	NULL
ZEBRA	NULL
and	NULL
ZEBRA/c-Fos	NULL
chimeras	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:1493-1504	NULL
.	NULL

Le	NULL
Roux	NULL
,	NULL
F.	NULL
,	NULL
A	NULL
.	NULL

Sergeant	NULL
,	NULL
and	NULL
L.	NULL
Corbo	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
EB1/Zta	NULL
protein	NULL
provided	NULL
in	NULL
trans	NULL
and	NULL
competent	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
productive	NULL
cycle	NULL
genes	NULL
does	NULL
not	NULL
activate	NULL
the	NULL
BZLF1	NULL
gene	NULL
in	NULL
the	NULL
EBV	NULL
genome	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

77:501-509	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1989	NULL
.	NULL

Responsiveness	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Not	NULL
]	NULL
repeat	NULL
promoter	NULL
to	NULL
the	NULL
Z	NULL
transactivator	NULL
is	NULL
mediated	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
by	NULL
two	NULL
independent	NULL
signal	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3040-3050	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Zta	NULL
transactivator	NULL
involved	NULL
in	NULL
induction	NULL
of	NULL
lytic	NULL
cycle	NULL
gene	NULL
expression	NULL
in	NULL
Epstein-Barr	NULL
virus-infected	NULL
lymphocytes	NULL
binds	NULL
to	NULL
both	NULL
AP-1	NULL
and	NULL
ZRE	NULL
sites	NULL
in	NULL
target	NULL
promoter	NULL
and	NULL
enhancer	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1143-1155	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Berk	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
Zta	NULL
transactivator	NULL
protein	NULL
stabilizes	NULL
TFIID	NULL
association	NULL
with	NULL
promoter	NULL
DNA	NULL
by	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:2441-2454	NULL
.	NULL

Marshal	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
C.	NULL
Sample	NULL
.	NULL

1995	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
3C	NULL
is	NULL
a	NULL
transcriptional	NULL
regulator	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:3624-3630	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
:	NULL
biology	NULL
,	NULL
pathogenesis	NULL
and	NULL
medical	NULL
as-pects	NULL
,	NULL
p.	NULL
1921-1958	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
R.	NULL
M.	NULL
Chanock	NULL
,	NULL
M.	NULL
S.	NULL
Hirsch	NULL
,	NULL
J.	NULL
L.	NULL
Melnick	NULL
,	NULL
T.	NULL
P.	NULL
Monath	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Ltd.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Mitchell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
in	NULL
mammalian	NULL
cells	NULL
by	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

Science	NULL
245:371-378	NULL
.	NULL

Qian	NULL
,	NULL
Z.	NULL
,	NULL
P.	NULL
Brunovskis	NULL
,	NULL
F.	NULL
Rauscher	NULL
III	NULL
,	NULL
L.	NULL
Lee	NULL
,	NULL
and	NULL
H.-J	NULL
.	NULL

Kung	NULL
.	NULL

1995	NULL
.	NULL

Transactivation	NULL
activity	NULL
of	NULL
Meq	NULL
,	NULL
a	NULL
Marek	NULL
's	NULL
disease	NULL
herpesvirus	NULL
bZIP	NULL
protein	NULL
persistently	NULL
expressed	NULL
in	NULL
latently	NULL
infected	NULL
transformed	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69	NULL
:	NULL
4037-4044	NULL
.	NULL

Rabson	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Heston	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1983	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
rare	NULL
Epstein-Barr	NULL
virus	NULL
variant	NULL
that	NULL
enhances	NULL
carly	NULL
antigen	NULL
expression	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80:2762-2766	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
T.	NULL
Ragot	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
spliced	NULL
BZLF1	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
transactivates	NULL
an	NULL
early	NULL
EBV	NULL
promoter	NULL
and	NULL
induces	NULL
the	NULL
virus	NULL
productive	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3109-3116	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Sarisky	NULL
,	NULL
R.	NULL
,	NULL
Z.	NULL
Gao	NULL
,	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
E.	NULL
D.	NULL
Fixman	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
D.	NULL
Hayward	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
replication	NULL
function	NULL
associated	NULL
with	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
transactivator	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:8340-8347	NULL
.	NULL

Schepers	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
Pich	NULL
,	NULL
J.	NULL
Mankertz	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1993.	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
DNA	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:4237-4245	NULL
.	NULL

40a.Schepers	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
Pich	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
transcription	NULL
factor	NULL
41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47.	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
AP-1	NULL
family	NULL
links	NULL
RNA	NULL
transcription	NULL
and	NULL
DNA	NULL
replication	NULL
in	NULL
the	NULL
lytic	NULL
cycle	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3921-3929	NULL
.	NULL

Schepers	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
Pich	NULL
,	NULL
and	NULL
W.	NULL
Hammerschmidt	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
of	NULL
oriLyt	NULL
,	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
DNA	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
,	NULL
by	NULL
BZLF1	NULL
.	NULL

Virology	NULL
220:367-376	NULL
.	NULL

Sista	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
J.	NULL
S.	NULL
Pagano	NULL
,	NULL
W.	NULL
Liao	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1993	NULL
.	NULL

Retinoic	NULL
acid	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
protein	NULL
(	NULL
BZLF1	NULL
)	NULL
that	NULL
mediates	NULL
disruption	NULL
of	NULL
latent	NULL
infection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:3894-3898	NULL
.	NULL

Taylor	NULL
,	NULL
N.	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
C.	NULL
Rooney	NULL
,	NULL
D.	NULL
Katz	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
BZLF1	NULL
latency-disrupting	NULL
gene	NULL
differs	NULL
in	NULL
standard	NULL
and	NULL
defective	NULL
Epstein-Barr	NULL
viruses	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1721-1728	NULL
.	NULL

Yates	NULL
,	NULL
L.	NULL
,	NULL
N.	NULL
Warren	NULL
,	NULL
D.	NULL
Reismann	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1984	NULL
.	NULL

A	NULL
cis-acting	NULL
clement	NULL
from	NULL
the	NULL
Epstein-Barr	NULL
viral	NULL
genome	NULL
that	NULL
permits	NULL
stable	NULL
replication	NULL
of	NULL
recombinant	NULL
plasmids	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:3806-3810	NULL
.	NULL

Zalani	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1996	NULL
.	NULL

Epstcin-Barr	NULL
viral	NULL
latency	NULL
is	NULL
disrupted	NULL
by	NULL
the	NULL
immediate-early	NULL
BRLF	NULL
protein	NULL
through	NULL
a	NULL
cell-specific	NULL
mechanism	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:9194-9199	NULL
.	NULL

Zhang	NULL
,	NULL
Q.	NULL
,	NULL
Y.	NULL
Hong	NULL
,	NULL
D.	NULL
Dorsky	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
S.	NULL
Zalani	NULL
,	NULL
N.	NULL
A.	NULL
Elshiekb	NULL
,	NULL
A.	NULL
Kiehl	NULL
,	NULL
T.	NULL
Le	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1996	NULL
.	NULL

Functional	NULL
and	NULL
physical	NULL
interactions	NULL
between	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
proteins	NULL
BZLF1	NULL
and	NULL
BMRF1	NULL
:	NULL
effects	NULL
on	NULL
EBV	NULL
transcription	NULL
and	NULL
lytic	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:5131-5142	NULL
.	NULL

Zhang	NULL
,	NULL
Q.	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
and	NULL
physical	NULL
interactions	NULL
between	NULL
p53	NULL
and	NULL
BZLF1	NULL
:	NULL
implications	NULL
for	NULL
Epstein-Barr	NULL
latency	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1929-1938	NULL
.	NULL

